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ABSTRACT 
Depressive disorders, more specifically major depressive disorder and dysthymia are 
serious, disabling illnesses. Approximately one in five persons is affected by a mood 
disorder at some point. My thesis examines the utilization rates of several pharmacologic 
and non-pharmacologic options of treatment for depression in a privately insured 
population in the US. The purpose of this study is to increase knowledge related to 
utilization patterns of pharmaceuticals or psychotherapy and yield recommendations to 
increase primary care capacity to deal with mental illnesses and acknowledge the 
variability of treatment in terms of geographical location and insurance type. Results 
indicate that large proportions of depressed children, adolescents and adults are not 
receiving any treatment or are receiving treatments unsupported or equivocally supported 
by empirical evidence. For insurance variation, managed care is more likely to utilize 
more established medication therapy with more robust evidence supporting their 
effectiveness. Finally, this study found large geographical variation that couldn't be 
explained on the basis of illness severity, guideline-concordance, or subject's 
Vl 
characteristics. The extent to which this variation reflects system inefficiencies or 
inappropriate care is discussed. 
Vll 
TABLE OF CONTENTS 
ACKNOWLEDGMENTS 
ABSTRACT 
TABLE OF CONTENTS 
LIST OF TABLES 
LIST OF FIGURES 
LIST OF ABBREVIATIONS 
SECTION 1: Introduction 
Problem Statement 
Conceptual Framework 
Pharmacotherapy Utilization 
Depression in Children and Adolescents 
Depression in Adults 
Study Aims and Hypotheses 
SECTION 2: Thesis Chapters 
Chapter 1 
Abstract 
Introduction 
Methods 
Results 
Discussion 
Vlll 
IV 
Vl 
Vlll 
X 
Xl 
xu 
1 
1 
3 
10 
11 
14 
15 
18 
18 
18 
20 
22 
27 
30 
Chapter 2 39 
Abstract 39 
Introduction 41 
Methods 43 
Results 50 
Discussion 61 
Chapter 3 70 
Abstract 70 
Introduction 72 
Methods 74 
Results 80 
Discussion 87 
SECTION THREE 94 
Final Summary Remarks 94 
BIBLIOGRAPHY 97 
CURRICULUM VITAE 110 
ix 
LIST OF TABLES 
Table 1. Insurance characteristics by class. 9 
Table 2. Treatment options for depression among children and adolescents. 35 
Table 3. Prevalence of antidepressant medication among C&A. 36 
Table 4. Predictors of receiving antidepressant treatment among C&A. 3 7 
Table 5. Antidepressants and antipsychotics by class. 46 
Table 6. Utilization rates of antidepressant treatment among adults. 55 
Table 7. Predictors of receiving antidepressant treatment among adults (bivariate). 57 
Table 8. Predictors of receiving antidepressant treatment among adults (multivariate). 59 
Table 9. State distribution by Region. 76 
Table 10. Treatment rates by geographical region and insurance type. 83 
Table 11. Odds of geographical region predicting treatment (fee-for-service). 84 
Table 12. Odds of geographical region predicting treatment ( capitated). 85 
Table 13. Odds of geographical region predicting treatment (PPO). 86 
X 
LIST OF FIGURES 
Figure 1. Gold's adaptation from the Institute ofMedicine Framework. 
Figure 2. Flowchart identification of adults with depression. 
Xl 
4 
45 
LIST OF ABBREVIATIONS 
C&A ....... ..................................... ..... ...... ........ .................. ... ........ . Children and Adolescents 
CDHP .. .................... .... ..... ..... .......................................... ... ... Consumer Driven Health Plan 
HDHP ....... .......... ...... .... ........... ..... .... .................................. .... . High Deductible Health Plan 
HMO ..... .. ........ ...... .... ..... ................................................. Health Maintenance Organization 
MC .. ..... ......... ..... ............. ..... ......... ........... ..... ............................. .................... Managed Care 
MDD ..... .. .. ... .... ... ............ ... ...... ........ ..... ... ... .......... .............. ...... . Major Depressive Disorder 
MHS ....... ..... ... .... ......... ........ ......... ... ........ ............ .... ..................... .. Mental Health Specialist 
NaSSA ...... .. .. .. .. ... .......... ...... ....... Noradrenergic and Specific Serotonergic Antidepressants 
NDRI ......... ......... ........... ...... ......... ......... Norepinephrine and Dopamine Reuptake Inhibitor 
OCD ....... ...... ....... ...... .............................. ... ......... ....... ..... ... Obsessive Compulsive Disorder 
PCP ........... .... ......... ..... ...... ...... .............. ..... ................................ ....... Primary Care Provider 
POS ................. ... ........... ..... ... ... ... ...... ... ... ...... ... .................................. ........ .. Point of Service 
PPO .............................................. ....................... ................. .. Patient Provider Organization 
SGA ............................. .... ......... ....... .... .... .... .............. ... .. Second Generation Anti psychotics 
SNRI .... ... ... ................. ............ ...... ........ ... Serotonin and Norepinephrine reuptake inhibitor 
SSRI ................... .............................................. ....... Selective Serotonin Reuptake Inhibitor 
TCA .... .... .. .. .... ...... ....... ...... ............. ................ ........................ ... .... Tricyclic Antidepressants 
Xll 
SECTION 1 
PROBLEM STATEMENT 
Most children, adolescents and adults with mental health problems do not receive 
the care they need to effectively manage their illness 1. Financial barriers, disease 
severity, and socioeconomic factors are frequently recognized as predictors of adherence 
and treatment initiation with medication among people with chronic conditions 2 . 
Nevertheless, other factors such as adherence to formularies and evidence-based 
guidelines, regional variability and insurance design remain underexplored and less 
understood. Non-guideline concordance to formularies from health providers is a 
common problem in healthcare, and greater in outpatient settings 3- 5. Often, literature 
recognizes differences between physician's specialties and treatment choices (e.g. 
physician's inertia and guideline-concordance when choosing treatment options). 
Moreover, guidelines to treat individuals with depression were developed under hospital 
settings and run by mental health specialists (MHS). However, the current reality of 
mental health care has shifted to outpatient settings, which are often managed by primary 
care providers (PCP). Consequently, PCPs are typically overburdened with additional 
demands to provide mental care with fewer resources, fewer support staff, additional 
budget constraints, and limited training, compared to specialists ' circumstances. 
The ambiguity of current guidelines to treat depression in adults plus the lack of 
consensus about which medication offers a better "maximum benefit/minimum risk" 
profile urges us to understand the predictors of such medication prescription and help 
elucidate this variability across regional and urban/rural settings. The reasons behind 
2 
treatment variability of depression across regions are unknown. The design of private 
insurance offers an array of subtle but significant features that may impact on the 
treatment choice of depression and little is known about the impact of the design of 
private insurance as related to treatment selection. 
Historically, mental disorders have often been neglected in regards to: (a) offering 
individuals evidence-based treatment and (b) management of mental disorders, which 
remains more art than science. The following proposal attempts to contribute to the 
literature by exploring the utilization frequency of several lines of pharmacological 
treatment, the insurance arrangements effect, and the regional composition influence 
among a privately insured population with depression. The key questions are: 
1. Do physician's prescribing practices reflect optimal treatment among a national 
representative sample of children and adolescents with depression? 
2. What is the effect of the benefit design features of insurance architecture as 
related to prescription choices among privately insured adults with depression? 
3. Does regional variation help explain the variability of treatment choice among 
privately insured adults with depression? 
3 
CONCEPTUAL FRAMEWORK 
In a market characterized by the growth of managed care, competition, quality, 
and accountability, access to health care is in the eye of the beholder. Since the model 
developed by Andersen and colleagues 6, discussion surrounding different ways to 
describe access to care in a health system remains controversial yet highly relevant 7. The 
following work will use an adaptation from Gold's framework of access, originally 
derived from the IOM conceptual framework (Figure 1) including concepts of regional 
variation. The framework has been used to explain access to care for chronic diseases, 
which demand a model capable of explaining continuity of care also an important factor 
of service utilization and guideline concordance. The model explains mediators of 
continuity as personal requirements, employer's preferences and system characteristics. 
Arguments persist that the practice of medicine remains uncorrelated to other 
factors different than strict scientific and evidence-based practice. However, early 
evidence from the Dartmouth Institute show the uneven and unpredictable quality of care 
provided in hospitals around the US 8. Regional variation is not something new in 
healthcare, but few studies have examined whether or not medication prescription 
practices reflect normative practice across the nation. 
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5 
Literature highlights that published guidelines do not always assure their 
appropriate dissemination and adoption throughout the medical community and the 
regional variability remains high 9- 12. For example, less aggressive treatment patterns are 
more common in the Northeast, compared to the South with underutilization of 
recommended mental services in the South as well 13 . A number of factors may play a 
role in explaining this variation: different managed care policies and plans with varying 
influences in the marketplace by region that include tailored industry marketing 
campaigns (e.g. medical representatives, gifts to providers), differing regional influences 
of physician specialty groups, the influence of direct-to-consumer advertising on patients 
and doctors, and different practice styles, values, and beliefs to practice medicine 9. Still, 
the reasons for this variation across treatment types warrant further research, Cox and 
colleagues 9 introduced "the professional uncertainty theory", contending that variation in 
treatment options is positively associated with the level of uncertainty surrounding the 
diagnosis. The source of information to choose the more adequate treatment options 
varies from site to site, from region to region, thereby introducing the variation in the use 
of different options available. 
Regarding urban/rural differences, the health and health care of rural Americans 
are more complex and more disadvantaged, compared to their urban counterparts in 
several important ways that affect their health. They are disproportionately poorer, fewer 
are of working age, and they have less education 14. The rural U.S. has 20 percent of the 
national population, but less than 11 percent of its physicians 15. Rural versus urban 
residents are more often uninsured (18.7 versus 16.3 percent), more likely to report being 
6 
in fair or poor health, have restricted activity, and lower levels of access to a regular 
primary care provider 15 . As a consequence, our model will analyze prescription patterns 
using four different regional regions across the US and identify the main prescription 
drivers by testing the interactions between urban/rural variability, physician's specialty, 
insurance design and psychotherapy utilization. 
For insurance design, we are analyzing an employer-based, privately insured 
population, our analysis will start at the point at which an individual needs to make a 
decision about joining a given health plan. Determinants of plan selection (financial and 
personal constructs) will measure demographic and socioeconomic items. The structural 
construct will measure variables weighting the pre-plan features (provider network, 
available choices, and market characteristics) and the post-plan characteristics (described 
in table 1). The inclusion of the post-plan characteristics reflects one's understanding of 
managed care (MC) and one's experience working within its constraints. It is important 
to recognize how much influence MC characteristics may have over access to care. For 
example, Goldston and colleagues found an association between the ability to navigate 
the system once you are enrolled and the ability to accessing additional services 16. 
Over the years, MC (a configuration of benefit design features offered through a 
contracted network assembled in many different ways 17) has become increasingly 
common, relegating traditional arrangements (fee-for-service) to less than 20% of the 
market share. In theory, managed care would raise quality of care while controlling 
excessive expenditure from the system. Evidence about the former statement remains 
controversial and has not been consistently proven 18- 22 . As the MC definition implies, 
7 
many different features differentiate the design of a plan type, as table 1 illustrates. Once 
an individual chooses a plan type, different features attached to it become available. 
If we describe the various plan choices as a continuum in regards to the most 
restrictive features to consumers, more restrictions on caregivers and less choice of 
providers, Health Maintenance Organizations (HMO) become the more restrictive option, 
often associated with fewer premium charges 18 . At the other end of the managed care 
spectrum, we find the Preferred Provider Organization (PPO) becoming more and more 
popular, even though its concept is fairly amorphous and industry tends to characterize it 
more by "what it is not (an HMO) than what it is" 17. The essence of the PPO is the 
preferred provider network, which is often misconstrued as the PPO "plan" 17. PPOs have 
the following features that make them different than HMOs including flexibility and 
customization: the benefits can be tailored more specifically on a case-by-case basis 
while HMOs often have more comprehensive (and more expensive) benefits which may 
not satisfy the subjects' employer. In a PPO, the component parts can be purchased 
separately. Even though the arrangement improves the relationship between providers 
and insurers (less intrusive in medical management and fewer disputes over payment 
practices) where they tend to have less leverage when negotiating product prices, 
compared to HMOs. Second, HMO's inability to sustain apparent cost savings is mainly 
because their higher administrative cost (PPOs' comparative price advantage). Third, it 
rur1s parallel with increased consumer risk share with more cost sharing, increased benefit 
buy down opportunities, multi-tier provider networks and consumer-driven health plan 
designs that align pretty well with the PPO. 
8 
The most classic plan design, fee-for-service remains the most flexible option, yet 
consistently shrinking its market share because of the lower accountability it provides. 
The Point of Service (POS) plan reflects a design that behaves differently according to 
each service. POS behaves as an HMO, other times more like a PPO. In more recent 
years newer designs have been implemented, called high deductible health plan (HDHP), 
transferring the risk of care from insurers to consumers and enhancing the ability of the 
individual to decide which services are worth their money (making the physician's advice 
optional rather than mandatory). These types of plans are usually coupled with a Health 
Savings Account (HSA), which is a tax advantaged, portable savings account owned by 
the employee and contributions are made by the employer. Typically, these plans have 
lower premiums and are most often used by young and healthy individuals. Outside 
managed care, fee-for-service still offers fewer restrictions in terms of choosing providers 
and institutions, but the model includes "higher volumes of services and more revenue to 
providers" and has become less popular for insurers, government agencies, and hospitals, 
who have become increasingly worried about the escalating costs of the healthcare 
system under this type of arrangement. Furthermore, quality is not a major contributing 
factor regarding fee-for-service reimbursement. As a consequence, this type of insurance 
coverage does not promote more accountability or systematic improved care on the 
providers side 17. 
Finally, the continuity of care described by this framework contains clinical and 
policy endpoints (health status, mortality, morbidity, well-being and equity to resource 
use). The Our source of information, the Truven Analytics database (previously known as 
9 
Thomson Reuters Marketscan) does not allow the analysis of these endpoints; therefore 
our analysis will evaluate structural and process variables only. The present work will try 
to elucidate the effect (if any) of selected variables described from the framework above 
involving prescription patterns and choices of antidepressants and anti psychotics, as well 
other predictors including sociodemographic plus clinical characteristics. 
Plan Type 
HMO 
POS 
PPO 
Fee-for-
service 
High 
Deductible 
Table 1. Insurance characteristics by class 
Incentives PCP Referrals Out of 
to use assigned from PCP Network 
certain to services 
providers specialists covered 
required 
Yes Yes Yes No 
Yes Yes Yes Yes 
Yes No nla Yes 
No No nla nla 
Varies No nla Varies 
Partially 
or fully 
capita ted 
Yes 
No 
No 
No 
No 
HMO: Health Management Organization POP: Point of Service PPO: Preferred Provider 
Organization. PCP: Primary Care Physician 
Source: Modified from Thomson Reuters Marketscan. Commercial Claims and Encounters 
Medicare SupplementaL Data Year 2009. 
10 
PHARMACOTHERAPY UTILIZATION 
It was unexpected to find a situation where the world utilizes so many medicines 
and the pattern and trends of their use is often so poorly understood. The uneasiness 
between the industry in general and government makes it difficult to accurately reflect 
drug usage; hence, the need by government agencies, academia, and civil society to 
identify other sources of information to track trends and set priorities considering 
regulatory policies, educational and cost-effectiveness strategies remains a challenge. The 
growth of health insurance systems and the production of massive amounts of records, 
designed initially for purposes of finances, administration and reimbursement, were 
gradually converted into terms more directly applicable to health services studies 23. 
Around 65% of the U.S. population is covered by some sort of private plan 2\ however, 
little is known about how much variation exists in relation to prescription patterns within 
the numerous insurance schemes provided by this type of coverage. 
Over the last two decades, there has been an increase in the number and types of 
antidepressant medications available and a decrease in psychotherapy treatment 25,26 . 
Pharmaceuticals targeted to treat depression have a wide range of mechanisms of action 
but primarily modulate the function of the neurotransmitters serotonin and/or 
norepinephrine and/or dopamine 27• Tricyclic and tetracyclic antidepressants (TCAs) 
were the first-line treatment choice for depression for many years before Fluoxetine's 
entry to the market. Since then, selective serotonin reuptake inhibitors (SSRis) became 
the initial choice of antidepressants in the majority of the developed world and 
consistently entering developing world guidelines and formularies. 
11 
DEPRESSION IN CHILDREN AND ADOLESCENTS 
Depressive illness in children and adolescents (C&A) is a major public health 
concern. A meta-analysis 28 of 26 epidemiologic studies with over 60,000 observations 
on children born between 1965 and 1996 found an estimated prevalence rate of major 
depressive disorder of 2.8% among children under age 13 and 5.6% among adolescents 
between 13 and 18 years. Depression is a critical factor for suicidal ideation, attempt and 
completion, which is the third leading cause of death among teenagers in the U.S. 29 . 
Approximately 60% of depressed youths report having thought about suicide and 30% 
actually attempt suicide 30. Nearly three-quarters of adolescents with major depressive 
disorder will relapse within five years, and are four times more likely to develop 
depression in adulthood 31 . Early onset of depression has been associated with treatment 
resistance 32. 
While there is considerable research targeting depression treatment across the 
public and private sector, there is lack of data regarding how treatment varies within the 
latter. Compared to the public sector, the private sector is characterized by more complex · 
systems of insurance, fewer incentives to use guidelines and higher risk of receiving 
newer antidepressants 25,33 . Such differences warrant further investigation to assess the 
appropriateness of treatment for depression among youth insured in the private sector. 
Because recommendations for the treatment of depression are primarily based 
upon safety and efficacy studies conducted in adult populations, most clinical practice 
guidelines suggest that the treatment of C&A depression should be more conservative 
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than adult treatment 5,34. Moreover, an increasing number of studies among patients 
younger than 18 years of age are rmsmg concern about the safety and efficacy of 
psychotropic medications, particularly antidepressants and antipsychotics, used to treat 
C&A with psychiatric disorders 35- 39. The effects of psychotropic agents on brain 
development have not been adequately delineated in humans 40, and the therapeutic 
effects of antidepressants vary significantly across age groups 41 . While untreated 
depression has substantial long-term consequences, unsafe and ineffective depression 
treatment also can have adverse outcomes. Therefore, clinical practice guidelines have 
focused on the best 'benefit to risk ratio' for C&A with depression 42 . 
In the last several years, attention to antidepressant treatment for children and 
adolescents has grown. First, the dominance of selective serotonin reuptake inhibitors 
(SSRis) over older treatments (tricyclic antidepressants, monoamine oxidase inhibitors) 
to treat C&A with depression has become well-established 40. Second, the general public 
is increasingly concerned about the safety and effectiveness of SSRis to treat suicidal 
ideation. This occurred after 2004, when the FDA released a black box warning for all 
SSRis, associating the drug class with an increased risk of suicidal ideation in C&A 43 ,44 . 
Third, in recent years, newer antidepressants (serotonin and norepinephrine reuptake 
inhibitors [SNRis] , noradrenergic and specific serotonergic antidepressants [NaSSAs], 
and norepinephrine and dopamine reuptake inhibitors [NDRis] have been marketed to 
physicians for the treatment of depressive illness in youths, even though published 
literature provides little to no rigorous evidence of effectiveness for these drugs. 
Similarly, although an increasing pattern of prescribing atypical antipsychotic 
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medications for children and adolescents with depression has been observed, this practice 
has no support from the FDA, from clinical practice guidelines, from rigorous research 
studies, or from institutional formularies. Interestingly, off-label drug use contributed to 
approximately 21% of prescriptions written annually in the U.S. in 2008. 45 
Findings from the adult literature suggest that combination treatment (medication 
and psychotherapy) for depression outperforms treatment with either therapy alone 46 or 
medication alone 47 . Similarly, the Treatment of Adolescent Depression Study (TADS) 
found the combination of fluoxetine and cognitive-behavioral therapy (CBT) to be more 
efficacious than either treatment alone while at the same time reducing the risk for 
suicidal thoughts. Moreover, in the Treatment of SSRI-Resistant Depression in 
Adolescents (TORDIA) study, teens who did not respond to a first antidepressant 
medication were more likely to improve if they were switched to a treatment that 
included both medication and psychotherapy. While these findings have not been 
consistently replicated (Goodyer 2007, Melvin 2006), the more favorable risk/benefit 
ratio of combination psychotherapy with fluoxetine supports this treatment approach as 
"optimal" for depressive illness in youths. 
In light of these developments, we sought to investigate the patterns of 
combination, psychotherapy, antidepressant, and antipsychotic treatment across physician 
specialty, insurance type, regional location, and individual characteristics among 
privately insured C&A diagnosed with depression. The principal aims of this thesis are 
to determine the extent to which depression treatment conforms to the extant evidence 
base, and to identify factors contributing to observed variations in treatment approaches. 
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DEPRESSION IN ADULTS 
Depressive disorders, including major depression and dysthymia, are serious disabling 
illnesses. Approximately one in five persons is affected by a mood disorder at some point 
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. The attendant economic costs to society and personal burden to patients and families 
are enormous. In the United States, the estimated costs of treating depression and the 
costs incurred by lost productivity exceeded $44 billion in 1990 49. The personal burden 
of depression includes higher mortality and impairment in multiple areas of functioning. 
The World Health Organization estimates that major depression is now the fourth most 
important cause world wide of loss in disability-adjusted life-years and is projected as the 
second most important cause by 2020 50. In the late 1980s, the U.S. Department of Health 
and Human Services sponsored the development of standard treatment guidelines for 
major depression. Since publication of the guidelines, widely publicized emphasis on 
recognizing and treating depression and development of many new pharmacotherapies 
has contributed to explosive growth in antidepressant prescribing and increasing 
pharmacy costs for health plans. 
Newer antidepressants and readily available herbal remedies have led to wider but 
sometimes confusing choices for clinicians. Physician specialty is often a key 
determinant of treatment selection among subjects with depression 51- 56 . Current health 
care delivery migration to primary care settings in the U.S. 57, and the escalating 
shortages of MHS all around the country 58,59,26 ,especially for pediatric patients, requires 
PCPs to provide treatment to patients that historically were managed by MHSs. 
Moreover, previous literature has systematically reported different treatment outcomes 
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across MHSs and PCPs 52 . For example, Gilbody and colleagues 55 found that although 
depression ranks third as the most common presenting problem in primary care settings, 
PCPs are less likely to follow treatment guidelines, compared to psychiatrists. 
Additionally, PCPs are not fully trained to recognize and treat depression nor suicidal 
intent, compared to psychiatrists 60,61 . 
STUDY AIMS AND HYPOTHESES 
First Chapter 
1. To investigate the patterns of utilization about psychotherapy, antidepressant, and 
antipsychotic treatment among privately insured C&A (6 to <18 years of age) 
with depression in 2009. 
Hl: C&A with depression are more likely to receive Fluoxetine, compared to other 
antidepressants and antipsychotic medication. 
H2: C&A with depression are less likely to receive psychotherapy, compared to 
pharmaceutical options of treatment, 
2. To determine the extent to which depression treatment conforms to the extant 
evidence base, and to identify factors contributing to observed variations in 
treatment approaches among privately insured Children and Adolescents with 
depression. 
H3: C&A with depression are more likely to receive pharmaceutical-only therapy, 
compared to optimal treatment (Fluoxetine + psychotherapy) 
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H4: MHS are more likely to choose less conservative treatment according to clinical 
guidelines, compared to PCPs. 
Second Chapter 
1. To compare and contrast antidepressant utilization across five different private 
insurance designs (Fee-for-service, PPO, HMO, POS, and HDHP) among 
privately insured adults (from 18 to 64 years of age) in 2011. 
H5: Adults under less restrictive health plans in terms of consumer choice of 
providers and networks are more likely to receive aggressive and off-label treatment 
options, compared to more restrictive health plans. 
H6: Adults under Capitated-based health plans are more likely to receive more 
conservative treatment according to clinical guidelines, compared to non-capitated 
health plans. 
2. To compare and contrast psychotherapy utilization and provider specialty among 
privately insured adults. 
H7: Adults under more restrictive health plans in terms of consumer choice of 
providers and networks are more likely to receive psychotherapy, compared to less 
restrictive health plans 
H8: Adults receiving treatment from PCPs are less likely to receive psychotherapy, 
compared to MHS. 
Third Chapter 
3. To compare and contrast the antidepressant utilization across four regional 
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clusters in the US (Northeast, West, South and Midwest), among privately 
insured adults ( 18 to 64 years of age) with depression in 2011. 
H9: Adults with depression residing in the Northeast will receive more conservative 
treatment options 13, compared to adults living elsewhere. 
4. To explore the association between antidepressant utilization and urban/rural 
settings, among privately insured individuals with depression in 2011. 
H1 0: Adults in urban settings will receive more aggressive treatment options, 
compared to adults living in rural settings. 
5. To explore the interactions between urban/rural settings, physician specialty, 
psychotherapy utilization and insurance architecture among privately insured 
individuals with depression in 2011. 
H 11: Individuals living in the Northeast will more likely receive psychotherapy and 
specialty care, compared to individuals living elsewhere. 
H12: The interaction between Urban/rural settings and the insurance design will 
show statistically significant differences of pharmacotherapy within regions 1 . 
1 The hypothesis remains broad on purpose. Past literature is scarce about the extent or direction 
of urban/rural settirlgs and their relationship with the insurance model. We aim to fill this research 
loop. 
SECTION 2: THESIS CHAPTERS 
CHAPTER!. 
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Does physicians' treatment of pediatric depression reflect evidence-based practice? 
Findings from a national sample of privately insured children and adolescents. 
ABSTRACT 
Objective. To examine the frequency of six approaches to the treatment of depression 
with varying degrees of empirical support in a national sample of privately insured 
children and adolescents (C&A). 
Methods. 
Data source. A privately insured population (MarketScan database) 
Design. Retrospective observational study of 2009 nationally representative data sample. 
Data subjects. Study sample included 61 ,599 C&A with depression, from a total of 
6,225,600 privately insured C&A in 2009. 
Measurements. The likelihood of receiving six different depression treatment options was 
assessed: combination treatment (fluoxetine and psychotherapy), first line antidepressant 
medication (fluoxetine), second line antidepressant medication (other SSRis), non-
evidence based newer antidepressants (SNRis, NaSSAs, NDRis), non-evidence-based 
SGAs, and psychotherapy alone. 
Data Analysis: Six mutually exclusive bivariate and multivariable logistic regression 
models were applied. 
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Results. Only 58.4% of depressed C&A received at least one type of depression 
treatment; 33.6% received psychotherapy alone; 24.8% received medication alone; and 
2.7% received combination treatment. Of those depressed C&A receiving medication, 
24.8% received medications unsupported by empirical evidence and 50.6 received 
medications with equivocal support. After controlling for individual characteristics, 
insurance type, region, and illness severity and complexity, mental health specialists 
(MHS) were more likely to prescribe combination treatment by approximately 9 fold 
(OR: 8.6; CI: 5.38-14.01), compared to primary care physicians (PCP). Other predictors 
of receiving combination treatment included major depressive disorder (MDD) diagnosis, 
early adolescent age group (12-14) and residing in the Northeast. 
Conclusions and Relevance. Our findings suggest that large proportions of depressed 
C&A are not receiving any treatment or are receiving treatments unsupported or 
equivocally supported by empirical evidence. Physicians should be guided by evidence of 
safety and effectiveness when considering treatment options for depressed youth. 
Keywords: antidepressants, psychotherapy, depression. 
Abstract word count: 274 
Manuscript word count: 3257 
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INTRODUCTION 
Depressive illness in children and adolescents (C&A) is a major public health 
concern. A meta-analysis 28 of studies conducted between 1965 and 1996 found an 
estimated prevalence rate of major depressive disorder (MDD) of 2.8% among children 
under age 13 and 5.6% among adolescents between 13 and 18 years. Depression is a 
critical factor for suicide, which is the third leading cause of death among teenagers in the 
U.S. 29 . Approximately 60% of depressed youths report having thought about suicide and 
30% actually attempt suicide 30. 
Since recommendations for the treatment of depression are based in part upon 
safety and efficacy studies conducted with adults, clinical practice guidelines for the 
treatment of depression in youth suggest that treatment approaches should be 
conservative 34 . The effects of psychotropic agents on brain development have not been 
adequately delineated in humans 62,63 , and the therapeutic effects of antidepressants vary 
significantly across age groups 41 . While untreated depression has substantial long-term 
consequences, unsafe and ineffective depression treatment also can have adverse 
outcomes. Therefore, clinical practice guidelines are promulgated for the best 'benefit to 
risk ratio' for C&A with depression. 
In the last several years, attention to antidepressant treatment for C&A has grown. 
First, the dominance of selective serotonin reuptake inhibitors (SSRis) over older 
treatments (tricyclic antidepressants, monoamine oxidase inhibitors) is well known 40 . 
Second, the general public is increasingly concerned about the safety and effectiveness of 
SSRis to treat depression after the 2004 black box warning by the FDA for all SSRis, 
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associating the drug class with an increased risk of suicidal ideation in C&A 43 . Third, in 
recent years, newer antidepressants (serotonin and norepinephrine reuptake inhibitors 
[SNRis], noradrenergic and specific serotonergic antidepressants [NaSSAs], and 
norepinephrine and dopamine reuptake inhibitors [NDRis]) have been marketed to 
physicians for the treatment of depressive illness in youths, even though published 
literature provides little to no rigorous evidence of effectiveness for these drugs. 
Similarly, although an increasing pattern of prescribing second-generation (atypical) 
antipsychotics (SGAs) for C&A with depression has been observed, this practice has no 
support from the FDA, clinical practice guidelines, rigorous research studies, or 
institutional formularies. Interestingly, off-label drug use contributed to approximately 
21% of prescriptions written annually in the U.S. in 2008 45 . 
While there is considerable research targeting depression treatment across the 
public and private sector, there is lack of data regarding how treatment varies for the 
latter. Compared to the public sector, the private sector is characterized by more complex 
systems of insurance, fewer incentives to use clinical practice guidelines, and higher risk 
of receiving newer antidepressants 33 . Such differences warrant further assessment of the 
relationships between insurance type and choice of depression treatment. 
In light of these factors, we sought to investigate the patterns of combination, 
psychotherapy, antidepressant, and antipsychotic treatment across physician specialty, 
insurance type, regional location, complexity and severity of the disease, and individual 
characteristics among privately insured C&A diagnosed with depression. The aim of the 
study was to determine the extent to which depression treatment conforms to the extant 
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evidence base, and to identify factors contributing to observed variations in treatment 
approaches. 
METHODS. 
Data 
We conducted a retrospective claims analysis on children and adolescents (6 to 
<18 years of age) at the time that a claim appeared. Annual data from 2009 were derived 
from Thomson Reuters MarketScan Database, a nationally representative data sample of 
individuals with employer-provided health insurance in the U.S., representing the 
medical experience of approximately 50 million covered lives, over 12 months. The 
database includes private sector health information of approximately 100 payers 
throughout all U.S. states. This study was approved by the Boston Medical Center 
Institutional Review Board. 
Inclusion/Exclusion criteria 
Table 1 summarizes the most common treatment options for C&A with 
depression. "Combination" treatment was identified by the Treatment for Adolescents 
with Depression Study (T ADS)36 as the most effective treatment to hasten remission of 
depressive symptoms while offering the most favorable benefit/risk profile 64,65 . 
Combination treatment also was found in the Treatment of Resistant Depression in 
Adolescents (TORDIA) study to be the most effective treatment for depression that is 
resistant to SSRI medication 66 • Fluoxetine, the only antidepressant approved by the 
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FDA for the treatment of depression in both C&A, has a consistently favorable risk-
benefit profile based upon available evidence 67,68, and as such is considered "first line" 
treatment. Treatment with antidepressants from the same class (SSRis) that have not 
been approved for both C&A is controversial 39,69. While some treatment guidelines and 
peer-reviewed publications suggest all SSRis as equally appropriate for the treatment of 
C&A with depression 70'71 , meta-analyses of multiple studies and most treatment 
guidelines support fluoxetine as the only appropriate option 39. As such, SSRI 
medications other than fluoxetine are considered "second line". The remaining drug 
types, which include newer antidepressants (NaSSAs, NDRis, SNRis) and SGAs, are not 
supported by empirical evidence of safety and efficacy for the treatment of depressed 
C&A, and as such are designated as "non-evidence based". The "psychotherapy alone" 
treatment option excluded any medication use. 
In this study, depression was defined using the ICD-9 codes for episodic mood 
disorders: major depressive disorder single episode (296.2), major depressive disorder 
recurrent episode (296.33), depressive disorder not otherwise specified (311 ), and 
dysthymia (300.4). 
Children and adolescents 6-17 years of age were identified as having a depressive 
disorder if a) they received at least two outpatient diagnoses of depression2 or one 
medication claim plus one diagnosis for depression; b) had a 6 month "clean period" 
without any diagnosis of depression or medication utilization; and c) had complete 2009 
insurance coverage to allow proper follow-up given the focus of the database. The 
2 Published literature has found low sensitivity to identify the correct primary diagnosis with just 
one outpatient diagnosis 72; hence, two diagnoses were used to improve the measure's sensitivity. 
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accuracy of claims data diagnosis for research purposes using these methods has been 
validated elsewhere, showing high positive predictive value 73 . Exclusions were a) 
children and adolescents with a diagnosis of bipolar (296.0x, 296.4x) or schizophrenia 
disorders (295.6x), and b) mixed disorders (depression + psychosis, or depression + 
bipolar), because they may appropriately receive SGA treatment, making it difficult to 
distinguish between antipsychotic medication used for treatment of psychotic symptoms 
versus depressive symptoms. Our final sample size consisted of 61,599 C&A who met 
our inclusion criteria. 
Analysis 
Medication data was extracted from the outpatient pharmacy claims using the 
National Drug Code (NDC). At least one claim for antidepressant or SGA medication 
was defined as "any medication use". Physicians were classified into two mutually 
exclusive categories: a) Mental Health Specialists (MHS), represented by psychiatrists 
and child psychiatrists, and b) Primary Care Physicians (PCP), represented by internists, 
pediatricians, family physicians and general practitioners. Other specialties and non-
physician professionals were excluded from the analysis. Psychotherapy utilization was 
identified by CPT codes (90804-90809, 90853 , 90847). Private insurance was classified 
as follows (Table 2): managed care coverage included individuals enrolled in a Health 
Maintenance Organization (HMO), Point-of-Service plan (POP), or Preferred Provider 
Organization (PPO); those enrolled in a non-managed insurance plan were classified as 
having fee-for-service coverage. We controlled for demographics including age 
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categorized into 3 groups (childhood [6-11 years] , early adolescence [12-14 years], and 
late adolescence [15- <18 years]); gender; geographical region clustered into 4 areas3 
(West, Midwest, South, Northeast); and mental health comorbidities (anxiety [ICD-9 
code 300.0], post-traumatic distress disorder [PTSD, ICD-9 code 309.81], attention-
deficit/hyperactivity disorder [ADHD, ICD-9 code 314.01], and suicidal ideation [ICD-9 
code V62.84]). Having more than one mental disorder has been identified in the literature 
as a proxy of complexity among depressed individuals 41 . Anxiety was used as the 
comparator group for other comorbid disorders because anxiety co-occurs often in 
patients with depression and is likely to be treated similarly (i.e., with antidepressant 
medication and psychotherapy) 74. 
Descriptive statistics are presented for the entire study population as well for 
strata defined by physician specialty, insurance type, and regional and individual 
variables. The percentages of subjects receiving each type of treatment were calculated 
(Table 3). Prevalence estimates utilized either one of the following denominators: a) the 
total number of C&A with depression as the denominator for those conditions including 
psychotherapy and b) the total number of C&A receiving at least one medication for 
those under pharmacologic treatment. Multiple logistic regression models with stable 
3 Regions were clustered using the Medical Expenditure Survey Panel method, data year 2009 as 
follows: 
1. Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, 
Pennsylvania, Rhode Island, and Vermont 
2. Midwest: Indiana, illinois, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North 
Dakota, Ohio, South Dakota, and Wisconsin 
3 South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, K entucky, 
Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, 
Virginia, and West Virginia 
4 West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, 
Oregon, Utah, Washington, and Wyoming 
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standard errors were constructed to study the independent effects of physician specialty, 
insurance type, illness severity, and regional and individual characteristics on the 
likelihood of depressed C&A receiving one of the six depression treatments (Table 1 ). 
Results are presented as adjusted odds ratios with 95% confidence intervals. 
Interaction was examined between the main independent variable of interest 
(physician specialty) and the other covariates. Interaction terms were ruled out from the 
model if they were not significant; also confounding was checked by assessing the 
association between the dependent and main independent variable with each covariate. 
Collinearity was examined among all covariates with the variance inflation factor not 
exceeding 10. The expected performance and stability of the models were measured by 
the C-statistic and the Hosmer-Lemeshow test respectively. 
All analyses were performed using person-level national weights constructed with 
the Household Component of the Medical Expenditure Panel Survey (MEPS), which 
provides estimates of the number of people with employer-sponsored private health 
insurance in the U.S. The person-level weights reflect the ratio of MEPS-based estimates 
in the different age/gender/region categories and the MarketScan number in the same 
category. In order to adjust our sample of interest so that its marginal totals match 
specified MEPS totals on the specified set of variables, we used the SAS Raking Macro, 
developed by Izrael and Colleagues 75 . Hence, our results are representative of the 
privately insured population in the U.S. The accuracy of the estimates between 
medication groups and the predictors of interest described in table 4 were tested using the 
methods by Bonferroni and the Bootstrap inference (10,000 bootstrap samples), applying 
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techniques described elsewhere 76 . The p-values for the association between treatment 
choices and all the predictors remained stable using either statistical method (data not 
shown). 
All analyses were run using SAS software, release 9.3 (SAS Institute, Cary, NC, 
1996). 
RESULTS. 
Table 3 reports the prevalence and the unweighted univariate predictors of type of 
treatment. A total of 24.8% of all depressed C&A received medication monotherapy. Of 
those, 23.5% received first line medication (fluoxetine), 50.6% received second line 
medications (other SSRis), 9.2% received newer antidepressants (SNRis, NDRis, 
NaSSAs), and 15.6% received SGAs. Combining all SSRis (first and second line) 
accounted for 74.1% of medication monotherapy treatment. Together, non-evidence 
based choices (SNRis, NDRis, NaSSAs, and SGAs) accounted for 24.8% of medication 
monotherapy treatment. About 1% of the medication monotherapy sample reported use of 
tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOis) (data not 
shown). Of all C&A with depression, 33.6 received psychotherapy alone and 2.7% 
received combination treatment (fluoxetine plus psychotherapy). 
For the unweighted univariate analysis, six characteristics were assessed (provider 
type, private insurance, age group, gender, region, and comorbidities). Overall, PCP 
reported an increased likelihood of choosing fluoxetine alone when compared to MHS 
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(p<O.OOl), but were less likely to choose combination treatment (p<O.OOI), 
psychotherapy alone (p<O.OOl) and SGAs (p<O.OOI). For insurance type, psychotherapy 
alone was less likely to be used in fee-for-service compared with HMOs (p<O.OOl). On 
the other hand, newer antidepressant treatment (p<O.OOI), SGA (p<O.OOl) and fluoxetine 
alone (p<O.OOOl) were more frequently used under fee-for-service arrangements, 
compared to HMOs. 
Table 4 reports the independent predictors on the multivariable logistic 
regression. Overall, provider type was the most consistent factor predicting treatment of 
depressed C&A. After controlling for demographics, comorbidities and illness severity, 
MHS were more likely to choose combination treatment (OR: 8.6; CI: 5.38-14.01); newer 
antidepressants (OR: 1.4; CI: 1.12-1.67); SGAs (OR: 2.1; CI: 1.69-2.70); and 
psychotherapy alone (OR:5.9; CI:5.22-6.77) compared to PCP. First line treatment was 
not utilized differently across specialties. 
Compared to HMO's, the odds of utilizing newer antidepressant options by PPO 
(OR:l.4; CI: 1.17-1.68) and POS (OR:1.6; CI:1.22-2.14) were significantly higher while 
SGAs were more likely to be used under fee-for-service coverage (OR:1.8;CI:l.l0-3 .04). 
In addition, PPOs were more likely to use fluoxetine alone (OR: 1.2; CI: 1.04-1.42) and 
less likely to use psychotherapy alone (OR:0.9;CI:0.82-0.95). Combination treatment and 
second line antidepressant treatment were similarly used across all plan types. 
Medication-only and combination regimens were less likely to be used with 
children compared to adolescents (except for first line antidepressant medication and 
SGAs), while psychotherapy alone was more likely to be used by children 
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(OR: 1.6;CI: 1.48-1 .67), compared to adolescents. The odds of receiving second line (OR: 
0.6; CI: 0.55-0.67) and newer antidepressants (OR:0.2; CI:0.19-0.30) were lower for 
children, compared to late adolescents while early adolescents were more likely to 
receive combination treatment (OR: 1.2; CI: 1.06-1.47) and first line antidepressant 
medication (OR: 1.2; CI:1.13-1.36) and SGAs (OR: 1.2; CI:1.04-1.28). Males were more 
likely to receive newer antidepressants (OR:1.2;CI:1.10-1.43) and SGAs (OR: 1.5; 
CI:1.33-1.75). , compared to females. For regional differences, the Northeast had a greater 
proportion of subjects receiving combination treatment than in any other region, while 
psychotherapy alone was more likely used in the West (OR: 1.2; CI:l.ll-1.36). , 
compared to the Northeast. 
In terms of comorbidities, compared to having a diagnosis of anxiety, those C&A 
with reported diagnoses of PTSD (OR:3.8; CI:1.59-9.21) and suicidal ideation (OR:3.4; 
CI:2.00-5.74) were more likely to receive SGAs, while utilization of psychotherapy alone 
was less likely among C&A with suicidal ideation (OR: 0.02; CI: 0.001-0.03). 
In terms of illness severity, compared to major depressive disorder, individuals 
with dysthymia were less likely to receive combination treatment (OR:0.5; CI:0.40-0.66); 
fluoxetine alone (OR:0.8; CI:0.70-0.99); other SSRis (OR:0.8; CI:0.74-0.92) and 
psychotherapy alone (OR:0.6; CI:0.53-0.63). Individuals with a diagnosis of unspecified 
depression were more likely to receive psychotherapy alone (OR:1.3; CI:l.15-1.39) and 
less likely to receive all other treatments. 
Statistically significant predictors of receiving combination treatment were MHS 
provider type, major depressive disorder (MDD) diagnosis, early adolescent age group, 
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and residing in the Northeast. Factors significantly associated with first line 
antidepressant treatment included MDD diagnosis, early adolescent age group, and PPO 
emollment. Second line treatment was associated with late adolescent age group, MDD 
diagnosis, residing in the Midwest and anxiety comorbidity. Predictors of receiving 
newer antidepressants included treatment by a MHS, PPO or POS emollment, late 
adolescent age group, male gender, MDD diagnosis, and residing in the Midwest. Those 
factors associated with SGAs utilization included MHS provider type, fee-for-service 
insurance coverage, early adolescent age group, male gender, PTSD diagnosis and 
suicidal ideation. Finally, factors associated with psychotherapy alone included MHS 
provider type, HMO insurance coverage, child or early adolescent age group, non-
specified depression and West or Northeast geographical region, while patients with 
suicidal ideation were less likely to receive psychotherapy alone. 
DISCUSSION 
The results from this study have important implications for policymakers, 
physicians, and patients. Nationally, two-fifths of privately insured C&A with depression 
did not receive any treatment, and less than five percent received combination treatment. 
Of C&A treated with medication, one-quarter received medications with little to no 
empirical support, while an additional one-half received medications with uncertain 
benefits. As such, physician practice for the treatment of depression among privately 
insured youths does not appear to be in alignment with the current evidence base. 
- - - - - ~~~~--
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Our findings corroborate previous published studies, signaling low utilization 
rates of combination treatment 69 . This finding reflects the well-documented difficulties 
associated with the delivery of psychotherapy in primary care settings 77 . Physician 
specialty has been recognized in this study as well as in previous research as a key 
determinant of treatment selection among younger populations 78 . Current health care 
delivery migration to primary care settings in the U.S. 57, and the escalating shortages of 
MHS all around the country 59• ,especially for pediatric patients, requires PCPs to provide 
treatment to patients that historically were managed by MHS. However, PCPs are 
typically overburdened with additional demands to provide mental health care with fewer 
resources, fewer support staff, additional budget constraints, and limited training, 
compared to specialists' circumstances 79. The Medical Outcomes Study reported that 
patients seen by psychiatrists had better functional outcomes 52, and Callahan et al. found 
that fewer than half of PCPs prescribe a treatment for their depressed patients, even 
though they had proper diagnostic scales and treatment algorithms 80. Further, medication 
alone with depressed patients is not always effective, and current reimbursement 
incentives for PCPs to offer psychotherapy as an alternative may not be worth the time 
and intensive labor that accompanies it 52 . 
Insurance coverage was significantly associated with four out of six treatment 
options, suggesting an association between less restrictive private insurance arrangements 
with higher rates of non-recommended medication options. Our data suggest that newer 
antidepressants and SGAs were more prevalent in fee for service and PPO insurance 
arrangements, the latter being the more flexible managed care option when considering of 
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specialist ' s availability, non-capitated payment arrangements, and not requiring pnor 
approval for medications. Managed care use of formularies may guide physicians to 
choose recommended treatments more often than more flexible insurance arrangements. 
For example, DeBar et al. 53 reported that adolescents enrolled in HMOs are more likely 
to receive treatment concordant protocols and prescription formularies, compared to 
adolescents covered by PPOs. 
With respect to age differences, second line antidepressants were more likely used 
in adolescents compared to children; this finding may derive from physicians' awareness 
of FDA approval of escitalopram to treat MDD beginning at age 12. In general, the age 
difference findings reflect a more conservative approach to the treatment of depression in 
younger compared to older youth. 
Effects of illness complexity on prescribing practices noted an increased 
likelihood of SGA prescription for those C&A with depression plus either PTSD or 
suicidal ideation even though SGAs lack empirical support for these indications. 
Although much less research has focused on treatments for the milder forms of 
depression (including unspecified depression and dysthymia), current guidelines 81,82 
suggest that treatment of mild depression should begin with psychotherapy. However, 
almost 20% of our sample was diagnosed with dysthymia and treated by one of the 
medication choices analyzed in this paper (data not shown). 
Several limitations of this study must be noted: First, we used claims data and 
may have under-identified patients with depression by excluding those who have an 
outpatient visit in which a depression diagnosis is not recorded. Second, some previously 
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recognized predictor variables (e.g., education, race) were not included in the analysis 
because of the nature of the data source 83 . Third, some psychotherapy offered in 
ambulatory settings may be delivered by non-physician providers who do not bill 
separately for their services; hence, we could potentially be underestimating 
psychotherapy utilization. Fourth, not all possible comorbid diagnoses were assessed. It is 
possible that less frequent comorbid conditions, such as disruptive behavior disorders, 
have an impact on choice of medication, including SGAs. However, their low frequency 
in the data did not allow separate analysis. 
Recognizing that the role of PCPs m identifying and treating children with 
emotional, behavioral, and developmental disorders will continue to increase m the 
context of a nationwide shortage of MHS, both the American Academy of Pediatrics and 
the American Academy of Child and Adolescent Psychiatry 84 have advocated the 
integration of mental health care into the pediatric medical home. One-quarter of C&A 
seen in the primary care setting and about one-half of all pediatric office visits involve 
behavioral, emotional, developmental, psychosocial, and/or educational concerns 84 . As a 
result, PCPs are on the front line in the effort to identify, diagnose, and treat psychiatric 
disorders in youth. Additional research is needed to better understand physicians' 
rationale for their choice of treatments for C&A with depression, and barriers to the 
wider use of treatments supported by evidence of safety and effectiveness. As the cost 
effectiveness of improving depression management in primary care has been suggested in 
previous studies 85; the integration of mental health services into primary care should be 
considered a public health priority. 
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Table 2. Treatment options for depression among children and adolescents 
Combination Treatment 
Fluoxetine + Psychotherapy 35 
First Line Antidepressant 
Proprietary Active Pharmaceutical FDA Approval 
Name Ingredient Class 
Prozac Fluoxetine SSRI 8 years and older 
Second Line Antidepressants * 
Celexa Citalopram SSRI 18 years and older 
Lexapro Escitalopram SSRI 12 - 17 years (for MDD only) 
Paxil Paroxetine SSRI 18 years and older 
Zoloft Sertraline SSRI 6 years and older (for OCD only) 
Luvox Fluvoxamine SSRI 8 years and older (for OCD only) 
Non-Evidence Based Medications 
Cymbalta Duloxetine SNRI 18 years and older (for MDD only) 
Savella Milnacipram SNRI Not approved for MDD in the U.S. , 
but it is in other countries 
Pristiq Desvenlafaxine SNRI 18 years and older (for MDD only) 
Effexor V enlafaxine SNRI 18 years and older (for MDD only) 
Wellbutrin Bupropion NDRI 18 years and older 
Remeron Mirtazapine NASSA 18 years and older 
Seroquel Quetiapine SGA Not approved for C&A depressive 
disorders 
Geodon Ziprasidone SGA Not approved for C&A depressive 
disorders 
Abilify Aripiprazo1e SGA Not approved for C&A depressive 
disorders 
Zyprexa Olanzapine SGA Not approved for C&A depressive 
disorders 
Risperdal Risperidone SGA Not approved for C&A depressive 
disorders 
* Escitalopram is approved by the FDA to treat MDD among adolescents; however, it is not 
approved for patients younger than 12 years of age.FDA: Federal Drug Administration, SSRI: 
Selective serotonin reuptake inhibitor, MDD: major depressive disorder, OCD: obsessive 
compulsive disorder, SNRI: serotonin and norepinephrine reuptake inhibitor, NaSSA: 
Noradrenergic and specific serotonergic antidepressants, NDRI: norepinephrine and dopamine 
reuptake inhibitor. 
Ta
bl
e 
3:
 P
re
va
le
nc
e 
o
f d
ep
re
ss
io
n 
tr
ea
tm
en
ts
 a
m
o
n
g 
pr
iv
at
el
y 
in
su
re
d 
c
hi
ld
re
n 
a
n
d 
ad
ol
es
ce
nt
s. 
D
ep
re
ss
io
n 
T
re
at
m
en
ts
, 
%
 
C
ha
ra
ct
er
is
tic
s 
U
nw
ei
gh
te
d 
C
om
bi
na
tio
n 
F
ir
st
 L
in
e 
Se
co
nd
 L
in
e 
T
hi
rd
 
SG
A
 
Ps
yc
ho
th
er
ap
y 
n
 
T
re
at
m
en
t 
L
in
e 
A
lo
ne
 
U
til
iz
at
io
n 
Fr
eq
ue
nc
y 
C
&
A
 u
si
ng
 a 
m
e
di
ca
tio
n 
o
pt
io
n 
15
26
4 
23
.5
 
50
.6
 
9.
2 
15
.6
 
A
ll 
C
&
A
 w
ith
 d
ep
re
ss
io
n 
61
59
9 
2.
7 
33
.6
 
Pr
ov
id
er
 T
yp
e 
Pr
im
ar
y 
C
ar
e 
Ph
ys
ic
ia
ns
 (P
CP
) 
15
11
2 
3.
3*
**
 
29
.6
* 
27
-8
 
26
 
14
.3
**
* 
4.
6*
**
 
M
en
ta
l H
ea
lth
 S
pe
ci
al
is
t (
M
RS
) 
99
48
 
27
.7
 
22
 
24
.2
 
25
.5
 
25
.5
 
18
.8
 
Pr
iv
at
e 
In
su
ra
nc
e 
Fe
e-
fo
r-
se
rv
ic
e 
87
2 
2 
4.
4*
 
10
.8
 
2.
3*
* 
5.
8*
 
34
.9
**
* 
PP
O
 
11
61
0 
1.
3 
4.
6 
9.
5 
2.
4 
3.
8 
31
.9
 
PO
S 
42
99
 
1.
3 
3.
8 
7.
9 
2.
6 
3.
9 
36
.4
 
H
M
O
 
40
47
4 
1.1
 
3.
8 
9 
1.
8 
3.
5 
36
 
A
ge
 g
ro
up
 
C
hi
ld
ho
od
 
83
95
 
1.1
 *
*
 
3.
8*
**
 
7.
1 *
*
*
 
1.1
 *
*
*
 
3.
8*
 
38
.
2*
**
 
Ea
rly
 A
do
le
sc
en
ce
 
15
70
8 
1.
7 
5.
4 
11
.1
 
2.
6 
4 
29
.6
 
La
te
 A
do
le
sc
en
ce
 
37
41
8 
1.
3 
4.
5 
11
.8
 
4.
1 
3.
3 
26
.7
 
G
en
de
r 
M
al
e 
26
12
1 
1.
3 
4.
3 
8.
6*
* 
2.
3 
4.
5*
**
 
34
**
 
Fe
m
al
e 
35
40
0 
1.
3 
4.
6 
9.
8 
2.
2 
2.
9 
32
.3
 
R
eg
io
n 
W
es
t 
12
50
6 
1.1
 *
*
 
4.
6*
* 
9*
**
 
2.
2*
**
 
3.
4 
37
.8
**
* 
So
ut
h 
19
91
7 
1.1
 
3.
9 
9 
2.
1 
3.
8 
28
.
9 
M
id
w
es
t 
22
17
4 
1.
5 
5 
10
.
9 
2.
9 
3.
9 
31
.7
 
N
or
th
ea
st
 
69
24
 
1.
9 
4.
4 
8 
2.
1 
3.
8 
37
.8
 
C
om
or
bi
di
tie
s 
PT
SD
 
14
8 
1.
3 
9.
2 
4.
4*
**
 
1.
2 
11
.4
**
* 
34
.1
 *
*
*
 
AD
HD
 
29
86
 
0.
8 
3.
7 
5.
7 
2.
6 
3.
4 
27
.1
 
Su
ic
id
e 
id
ea
tio
n 
57
2 
0 
5.
7 
12
.4
 
3.
9 
11
.4
 
0.1
 
A
nx
ie
ty
 
24
14
 
1.
3 
4.
6 
14
.
6 
2.
3 
3.
5 
29
.1
 
*
*
*
 S
ig
ni
fic
an
ce
 a
t p
<
.
OO
Ol
 *
*
 S
ig
ni
fic
an
ce
 a
t p
<
O.
Ol
 *
 S
ig
ni
fic
an
ce
 a
t p
<
0.
05
 
I I i 
w
 
0'
\ 
Ta
bl
e 
4. 
Pr
ed
ic
to
rs
 o
f r
ec
ei
vi
ng
 d
iff
er
en
t o
pt
io
ns
 fo
r d
ep
re
ss
io
n 
tr
ea
tm
en
t 
Pr
ed
ic
to
r 
C
om
bi
na
tio
n 
Fi
rs
t L
in
e 
Se
co
nd
 L
in
e 
N
ew
er
 
T
re
at
m
en
t 
A
nt
id
ep
re
ss
an
t 
A
nt
id
ep
re
ss
an
t 
A
nt
id
ep
re
ss
an
t 
T
re
at
m
en
t 
T
re
at
m
en
t 
T
re
at
m
en
t 
(S
NR
is,
 N
aS
SA
s, 
N
D
R
is
) 
O
R 
(95
% 
CI
) 
O
R 
(95
% 
CI
) 
O
R 
(95
% 
CI
) 
O
R 
(95
% 
CI
) 
Pr
ov
id
er
 T
yp
e 
M
en
ta
l H
ea
lth
 
8.
6 
(5.
38
 to
 1
4.
01
)**
* 
0.
8 
(0.
71
 to
 l.
OO
)b 
1.1
 (0
.98
-1.
2) 
1.
4 
(1.
12
 to
 1
.6
7)*
* 
Sp
ec
ia
lis
ts 
(M
HS
) 
Pr
im
ar
y 
Ca
re
 
Ph
ys
ic
ia
ns
 (P
CP
) 
(R
G)
 
Pr
iv
at
e 
In
su
ra
nc
e 
Fe
e-
fo
r-s
er
vi
ce
 
1.
7 
(0.
75
 to
 3
.9
1) 
1.1
 (0
.69
 to
 1
.7
9) 
1.2
 (0
.85
 to
 1
.7
1) 
1.
2 
(0.
74
 to
 1
.9
4) 
PP
O
 
1.2
 (
0.9
3 t
o 
1.
65
) 
1.
2 
(1.
04
 to
 1
.4
2)*
 
1.1
 (0
.98
 to
 1
.2
0) 
1.
4 
(1.
17
 to
 1
.6
8)*
* 
PO
S 
1.
0 
(0.
65
 to
 1
.6
4) 
0.
9 
(0.
75
 to
 1
.2
8) 
0.9
 (0
.76
 to
 1
.0
8) 
1.
6 
(1.
22
 to
 2
.1
4)*
* 
H
M
O
 (R
G)
 
A
ge
 g
ro
up
 
Ch
ild
ho
od
 
0.8
 (
0.6
2 t
o 
0.
99
)**
* 
0.9
 (0
.81
 to
 1
.
06
) 
0.
6 
(0.
55
 to
 0
.6
7)*
**
 0
.2
 (0
.19
 to
 0
.3
0)*
**
 
Ea
rly
 A
do
le
sc
en
ce
 1
.2
 (
1.0
6 t
o 
1.
47
)**
* 
1.
2 
(1.
13
 to
 1
.3
6)*
**
 
0.
9 
(0
.
91
 to
 1
.0
4) 
0.
6 
(0.
55
 to
 0
.7
0)*
**
 
La
te
 A
do
le
sc
en
ce
 
(R
G)
 
G
en
de
r 
M
al
e 
1.
0 
(0
.
85
 to
 1
.3
0) 
0.
9 
(0
.
86
 to
 1
.0
9) 
0.
97
 (0
.
89
 to
 1
.
05
) 
1.
2 
(1.
10
 to
 1
.4
3)*
* 
Fe
m
al
e 
(R
G)
 
R
eg
io
n 
W
es
t 
0.
6 
(0.
40
 to
 0
.8
1)*
* 
0.
95
 (0
.
77
 to
 1
.1
) 
1.0
 (
0.8
5 
to
 1
.1
5) 
0.
9 
(0
.
75
 to
 1
.1
9) 
So
ut
h 
0.
6 
(0.
46
 to
 0
.8
7)*
* 
0.
81
 (0
.66
 to
 0
.9
8)*
**
 1
.0
3(0
.90
 to
 1
.1
9) 
0.
9 
(0.
78
 to
 1
.1
8) 
M
id
w
es
t 
0.
8 
(0.
60
 to
 1
.1 
0) 
1.1
 (0
.
93
 to
 1
.3
5) 
1.
3 
(1.
16
 to
 1
.5
2)
*
*
*
 
1.
3 
(1.
10
 to
 1
.6
4)*
**
 
N
or
th
ea
st 
(R
G)
 
Co
m
or
bi
di
tie
s 
PT
SD
 
2.
5 
(0
.
51
 to
 1
2.
51
) 
2.
4 
(0.
82
 to
 6
.
76
) 
0.3
 (0
.15
 to
 0
.6
0)*
**
 0
.
6 
(0
.
16
 to
 2
.1
4) 
AD
HD
 
0.
6 
(0.
26
 to
 1
.
26
) 
0.8
 (0
.54
 to
 1
.2
1) 
0.4
 (0
.28
 to
 0
.4
8)*
**
 1
.
3 
(0.
82
 to
 2
.0
0) 
Su
ic
id
e 
id
ea
tio
n 
-
1.5
 (0
.90
 to
 2
.5
6) 
1.
0 
(0.
64
 to
 1
.4
6) 
1.
6 
(0.
89
 to
 2
.9
8) 
A
nx
ie
ty
 (R
G)
 
SG
A
 
T
re
at
m
en
t 
O
R 
(95
% 
CI
) 
2.
1 
(1.
69
 to
 2
.7
0)*
**
 
1.
8 
(1.
10
 to
 3
.0
4)
* 
1.1
 (0
.93
 to
 1
.3
1) 
1.1
 (0
.86
 to
 1
.5
0) 
1.
0 
(0.
90
 to
 1
.2
0) 
1.
2 
(1.
04
 to
 1
.2
8)*
 
1.
5 
(1.
33
 to
 1
.7
5)
**
* 
0.9
 (0
.70
 to
 1
.1
3) 
1.
0 
(0.
79
 to
 1
.
23
) 
1.0
 (0
.83
 to
 1
.2
7) 
3.
8 
(1.
59
 to
 9
.2
1)*
**
 
0.
9 
(0.
55
 to
 1
.3
6) 
3.
4 
(2.
00
 to
 5
.7
4)*
**
 P
sy
ch
ot
he
ra
py
 A
lo
ne
 
O
R 
(95
% 
CI
) 
5.
9 
(5.
22
 to
 6
.7
7)*
**
 
1.
0 
(0.
73
 to
 1
.2
5) 
0.
9 
(0.
82
 to
 0
.9
5)*
* 
0.
9 
(0.
85
 to
 1
.
09
) 
1.
6 
(1.
48
 to
 1
.6
7)*
**
 
1.
1 
(1.
06
 to
 1
.1
7)
*
*
*
 
1.
0 
(0.
92
 to
 1
.0
4) 
1.
2 
(1.
11
 to
 1
.3
6)*
**
 
0.8
 (0
.75
 to
 0
.9
1)*
**
 
0.8
 (0
.76
 to
 0
.9
2)*
**
 
1.1
 (0
.
58
 to
 2
.
00
) 
1.0
 (0
.77
 to
 1
.1
7) 
0.
02
 (0
.00
1 
to
 0
.0
3)*
**
 w
 
-
.
.
.
J 
D
is
ea
se
 se
v
e
rit
y 
D
ys
th
ym
ia
 
0.
5 
(0.
40
 to
 0
.6
6)*
**
 
0.
8 
(0.
70
-0.
99
)* 
0.8
 (0
.74
-0.
92
)**
 
0.
9 
(0
.
75
-
1.
08
) 
1.1
 (0
.97
-1
.47
) 
0.
6 
(0.
53
-0.
63
)**
* 
U
ns
pe
ci
fie
d 
0.
6 
(0.
44
-0.
82
)**
 
0.
6 
(0.
52
-0.
79
)**
* 
0.
7 
(0.
61
-0.
80
)**
* 
0.
6 
(0.
52
-0.
80
)**
* 
0.
7 
(0.
54
-0.
90
)**
 
1.
3 
(1.
15
-1.
39
)**
* 
de
pr
es
si
on
 
M
ajo
r d
ep
re
ss
iv
e 
di
so
rd
er
 (
RG
) 
C-
st
at
is
tic
 
0.
69
 
0.
62
 
0.
64
 
0.
66
 
0.
68
 
0.
73
 
H
os
m
er
-
0.
43
 
0.
19
 
0.
22
 
0.
79
 
0.
88
 
0.
91
 
Le
m
es
ho
w
 (p
-
v
al
ue
) 
PT
SD
: 
Po
st
 T
ra
um
at
ic
 S
tre
ss
 D
is
or
de
r; 
A
D
H
D
: 
A
tte
nt
io
n 
D
ef
ic
it 
H
yp
er
ac
tiv
ity
 D
is
or
de
r 
R
G
: 
R
ef
er
en
ce
 G
ro
up
. 
*
*
*
 
Si
gn
ifi
ca
nc
e 
at
 
p<
.O
OO
l *
*
Si
gn
ifi
ca
nc
e 
at
 p
<
O.
Ol
 *
Si
gn
ifi
ca
nc
e 
at
 p
<
0.
05
 b
: B
or
de
rli
ne
 si
gn
ifi
ca
nt
. 
w
 
0
0
 
39 
CHAPTER2. 
The effect of insurance "restrictedness" and physician specialty on privately insured 
adults with depression. 
ABSTRACT 
Objective. The purpose of this study was to assess the relationship between utilization 
rates of different treatment options (antidepressants, antipsychotics and/or 
psychotherapy) and insurance arrangements among privately insured adults in the U.S. 
Methods. 
Data source. A privately insured population (Truven Analytics 2011) 
Design. Retrospective observational study of2011 nationally representative data sample. 
Data subjects. Study sample included 753,007 adults with depression. 
Measurements. The likelihood of receiving six different depression treatment options was 
assessed: combination treatment (any medication and psychotherapy), SSRis, TCAs, 
SNRis, NDRI, NaSSA, SGAs, and other antidepressants. 
Data Analysis: Nine mutually exclusive bivariate and multivariable logistic regression 
models were applied. 
Results. Only 14% of adults with depression received at least one type of medication 
treatment; from those, 32% received NDRI, 23% received SSRis; 17% received SNRis, 
15% received TCAs, 8% received other antidepressants, 3% received NASSA and 2% 
received SGAs. About 11% received psychotherapy treatment and 1.1% received 
combination therapy. After controlling for individual characteristics, insurance type, 
region, residential area, mental health carve-out, medication copayment, treatment 
compliance and illness severity and complexity, capitated arrangements were more likely 
40 
to prescribe combination treatment by approximately 2 fold (OR: 1.89; CI: 1.47-2.44), 
compared to fee-for-service arrangements. Other predictors of receiving combination 
treatment included being seen by a MHS, receive carve out mental health services, reside 
in the West or the Northeast and having a diagnosis of dysthymia. 
Conclusions and Relevance. Our results suggest that more established medication 
therapy with more robust evidence supporting their effectiveness are being used in 
Managed Care settings. Mental health recommendations by current guidelines and PCP's 
busy schedules seem to move in opposite directions. Even though some form of 
psychotherapy plus the combination of evidence-based medications still offers the 
maximum benefit while minimizing risks for adults with mild to moderate depression, 
primary care does not have the time nor the proper training to facilitate such an approach. 
Short and long-term recommendations are further discussed to tackle this deficit. 
41 
INTRODUCTION 
Major Depressive Disorder (MDD) and dysthymia are serious disabling maladies. 
Approximately 20% of persons in the world are affected by a mood disorder at some 
point. 48 Depression is among the four leading causes of years lived with disability, 
according to WHO. 86 In the late 1980s the U.S. department of Health and Human 
Services developed the first clinical guideline to treat MDD in a standardized way. 
Emphasis on diagnosing and treating depression has contributed to the discovery of 
dozens of pharmacologic options with positive effects reducing symptom severity 
(compared to placebo), which has also increased pharmacy costs for health plans rapidly. 
Newer classes of antidepressants and off-label utilization of antipsychotics has led to 
wider but often confusing choices for prescribing providers. Additionally, current and 
older guidelines emphasize the need to initiate therapy with "psychotherapeutic support", 
which should be continued throughout the entire treatment. 5•82 The latter approach 
decreases the odds of resistant depression and increases the chances of successful 
treatment. 82 
With respect to antidepressants, approximately 40 compounds are available 
worldwide and evidence tends to make them comparable in terms of antidepressant 
efficacy when treating adults (treatment responses around 50-75%).82 However, 
according to the latest literature, newer antidepressants (e.g. selective serotonin reuptake 
inhibitors (SSRI), selective serotonin and norepinephrine reuptake inhibitors (SNRis), 
noradrenaline and dopamine reuptake inhibitor, NDRI), tend to have fewer or less serious 
side effects compared to their older counterparts (e.g. tricyclic antidepressants (TCA), 
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monoamme oxidase inhibitors (MAOI)) 27•87 . Therefore, the scientific selection of a 
particular antidepressant depends on vanous factors: patient's pnor expenence, 
concurrent medical conditions, possible interactions with co-medication, physician's 
experience with medication, patient's preference, cost, and availability. 82 The selection 
of therapy is likely to lower the incidence of side effects, may lessen the need for 
changing therapies, enhance patient compliance to medication, and reduce overall health 
care costs. 88 
For off-label medication, literature shows an important increase of second 
generation antipsychotics in both adults and particularly children, even though the side 
effects can be fatal 89•90. It's not clear whether the increase is driven by the lack of 
efficacy of on-label antidepressants, higher rates of resistant depression in the general 
population or other factors such as financial incentives or different styles of practicing 
medicine across regions. 
It is often assumed that the physician-patient encounter is provided under two 
premises: first, scientific norms based on previously tested and proven treatments are the 
only drivers of the interaction; second, the encounter is not driven by insurance 
arrangements or technology availability. In the real world however, individual attitudes 
of providers and insurance coverage influence the encounter as strongly as science. 8 
Such determinants help explain why two comparable patients with mild depression will 
receive two different courses of treatment if seen by a specialist or generalist. It also 
affects whether a provider will choose a particular medication option depending upon the 
type of insurance a person has. There are numerous examples in the literature describing 
43 
how subjective considerations play an important role when choosing treatment options. 
For example, region or state level data in the US suggest that the strongest predictor of 
per capita costs (measured by per capita admission rates) were the opinions held by 
physicians about the need for hospitalization. 91,92 Also, previous experience with a 
particular treatment and patient preferences play a role in the treatment choice. 93 ,94 
With respect to insurance coverage, private insurance settings remain 
underexplored compared to their public counterparts. The design of private insurance 
offers an array of subtle but significant features that may impact the treatment choice for 
depression. However, little is known about the impact of the design of private insurance 
plans as related to treatment selection. Historically, mental disorders have often been 
neglected in regards to: (a) offering individuals evidence-based treatment and (b) 
management of mental disorders, which remains more art than science. 95 
The purpose of this study was to assess the relationship between utilization of 
different treatment options (antidepressants, antipsychotics and/or psychotherapy) and 
insurance arrangements in the US, controlling for patient severity, complexity, 
pharmaceutical copayment, geographical location, compliance, and demographic 
characteristics in privately insured adults with depression. 
METHODS 
A cross sectional analysis was developed using a commercially available national 
data source (Truven Analytics Database) to identify a retrospective cohort of patients 
receiving an antidepressant to treat a new episode of mild or severe cases of depression in 
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2011. Using claims from the outpatient data source, patients between 18 to 64 years of 
age with new episodes of depression were identified according to the following criteria: 
(1) a claim indicating a primary or secondary (ICD-9-CM) diagnostic code of 296.2 or 
296.3 or 311 or dysthymia 300.4 (2) a 6 month "clean period" without a medication claim 
(antidepressants and/or antipsychotics) before the depression claim date (3) at least 6 
months without a depression diagnosis(es) or receipt of psychotherapy services (2 or 
more visits) before the depression claim date ( 4) at least twelve months of insurance 
coverage to ensure completeness (Figure 1 ). These inclusion criteria follow 
recommendations from the Health plan Employer Data Information System (HEDIS) for 
defining and measuring new episodes of depression. 96 This study was approved by the 
Boston Medical Center Institutional Review Board. 
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Figure 2. Flowchart identification of adults with depression. 
I Exclu ,.~ . .J I N of adults with depression(18-64) 
(2010-201 1) 
1,717,645 
I 
6 months ~clean period" 
(without dx or medication) 
and 
at least 12 months of follow-up data 
962,249 
755,396 I 
Depression criteria~ 
Two outpatient dx of depression 
or 
Medication claim + one dx of depression 
755,393 
206,856 I 
L Exclusion of Bipolar, Squizophrenia and Psychosis related dx I 
2389 
I 1 N of adults (18-64) with a firsttime diagnosis of depression 753,007 
647,758 
At least one Medication Treatment: 
SSRI ,SNRI,NDRI,TCA,NASSA, SGA, MISC 
105,249 
+ 
I N of adults (18-64) with a diagnosis of depression, and medication treatment (201 0-2011) I 105 249 (Prevalence:13.98%) 
Dependent variable: medication utilization 
Medication data was extracted from the outpatient pharmacy claims using the 
National Drug Code (NDC). At least one claim for antidepressant or SGA medication 
was defined as "any medication use". Seven medication groups were identified and 
analyzed: (1) SSRis (2) TCAs (3) SNRis (4) NDRI (5) NaSSA (6) SGAs and (7) 
Miscellaneous. The Combination category considered at least one medication claim and 
at least one session of psychotherapy after the diagnosis index. Table 1 reports the 
specific pharmaceuticals by class. 
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Table 5. Antidepressants and antipsychotics by class 
Proprietary N arne Active Ingredient Class Generation 
SSRis 
Celexa Citalopram 
Lexapro Escitalopram 
Paxil Paroxetine 
Zoloft Sertraline 
Luvox Fluvoxamine 
Prozac Fluoxetine 
Viibrid Vilazodone 
SNRis 
3rd Generation Cymbalta Duloxetine 
Savella, Dalcipran Milnacipran 
Pristiq Desvenlafaxine 
Effexor V enlafaxine 
Reductil Sibutramine 
Serzone Nefazodone 
Fetzima Levomilnacipran 
SGAs 
Seroquel Quetiapine 
Geodon Ziprasidone 
Abilify Aripiprazole Off-Label Zyprexa Olanzapine 
Risperdal Risperidone 
Clozapine Clozapine 
NASSAs 
Remeron Mirtazapine 
NDRI 2nd Generation 
Wellbutrin Bupropion 
TCAs 
Elavil, Endep, Levate Amitriptyline 
As en din Amoxapine 
Anafranil Clomipramine 
Norpramin, Pertofrane Desipramine 
Adapin, Sinequan Doxepin 
Tofranil Imipramine 1st Generation 
Deprilept, Ludiomil, Psymion Mll2Totiline 
Pamelor Nortriptyline 
Vivactil Protriptyline 
Surmontil Trimipramine 
Miscellaneous 
Strattera Atomoxetine (Norepinephrine reuptake Inhibitor) 
Buspar Buspirone (5HT1A receptor agonist) 
Nefadar, Serzone Nefazodone (5HT2-receptor antagonist) 
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Desyrel, Apo-Trazodone, Trazodone (5HT2-receptor antagonist, 
Oleptro triazolopyridine-derivati ve) 2"d Generation 
ludiornil maprotiline 
SSRI: Selective serotomn reuptake mhibrtor, SNRI: serotorun and norepmephrine reuptake 
inhibitor, NaSSA: Noradrenergic and specific serotonergic antidepressants, NDRI: 
norepinephrine and dopamine reuptake inhibitor, SGA: Second Generation Antipsychotics, TCA: 
Tricyclic Antidepressants. 
Patients were classified into one of these 8 mutually exclusive treatment groups 
based on the first class of antidepressant they received within 30 days of their episode 
diagnosis date. Patients who received an antidepressant within 30 days of their depression 
diagnosis but were initiated on more than 1 class that day, or were initiated on an 
antidepressant 30 days after their diagnosis, were excluded from the study cohort. 
The main independent variable of this study was the type of insurance plan. Five 
different categories were further analyzed: 1) Fee-for-service: the least restrictive plan in 
terms of out-of-network service and specialist's availability. 2) Capitated Health 
Maintenance Organizations (HMO) or Point of Service (POS): The most restrictive 
option when considering specialty availability and out of network services. 3) Patient 
Provider Organizations: Individuals have financial incentives to use a particular list of 
providers. They can seek care outside network though. 4) Non-capitated POS: Each 
encounter behaves differently. PCPs are required for referral to specialists. 5) High 
Deductible Health Plans: Behaves as a PPO plus a Health Savings Account or Health 
Reimbursement Arrangement. Expect for fee-for-service, all insurance arrangements are 
considered "Managed Care" (MC). Table 2 describes the specific characteristics by plan 
type. 
We measured the likelihood of receiving psychotherapy while using the different 
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types of antidepressant medication. Psychotherapy utilization was identified by CPT 
codes (90804-90809, 90853, 90847). Physicians and non-physicians were classified into 
two mutually exclusive categories: a) Mental Health Specialists (MHS), represented by 
psychiatrists, child psychiatrists, psychologists and nurse psychologists and b) Primary 
Care Physicians (PCP), represented by internists, pediatricians, family physicians, 
general practitioners and nurses. Psychotherapy utilization was identified by CPT codes 
(90804-90809, 90853, 90847). Among demographic characteristics, we considered age, 
categorized into 3 groups (young adults [18-26 years], adults [27-44 years], and older 
adults [45- 64 years]); gender (male/female); patient's geographical region clustered into 
4 areas § (West, Midwest, South, Northeast); and patient's urban or rural residence. 
Severity and complexity of subjects was assessed by: a) a severity index identifying 
three different depression diagnoses: major depressive disorder, dysthymia, and 
unspecified depression; b) The main reason of the visit; c) The Elixhouser comorbidity 
Index 97; d) The existence of carve-out for mental illness and substance abuse. Having 
more than one mental disorder has been identified in the literature as a proxy for 
complexity among depressed individuals. 41 As a proxy of adherence to guidelines from 
the patient's perspective, we calculated the number of months an individual kept 
§ Regions were clustered using the Medical Expenditure Survey Panel method, data year 2009 as 
follows: 
1. Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, 
Pennsylvania, Rhode Island, and Vermont 
2. Midwest: Indiana, illinois, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North 
Dakota, Ohio, South Dakota, and Wisconsin 
3 South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, 
Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, 
Virginia, and West Virginia 
4 West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, 
Oregon, Utah, Washington, and Wyoming 
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receiving the treatment choice. We considered an individual adherent if they had at least 
6 months of pharmacy claims, allowing for no more than two months of discontinuation 
within the 6-month time frame. 
Descriptive statistics are presented for the entire study population as well for 
strata defined by insurance type, physician specialty, patient severity, patient complexity, 
regional and demographic variables. The percentages of subjects receiving each type of 
treatment were calculated (Table 3). Prevalence estimates utilized either one of the 
following denominators: a) the total number of adults with depression as the denominator 
for those conditions including psychotherapy; b) the total number of adults receiving at 
least one medication for those under pharmacologic treatment. Multiple logistic 
regresswn models calculated the estimates of the independent effects of physician 
specialty, insurance type, illness severity, and regional and individual characteristics on 
the likelihood of adults receiving one of the eight depression treatments. Results are 
presented as adjusted odds ratios with 95% confidence intervals. 
Interactions were examined between the main independent variable of interest 
(insurance arrangements) and regional variables. Interaction terms were ruled out from 
the model if they were not significant; also confounding was checked by assessing the 
association between the dependent and main independent variable with each covariate. 
Collinearity was examined among all covariates with the variance inflation factor not 
exceeding 10. The expected performance and stability of the models were measured by 
the C-statistic and the Hosmer-Lemeshow test respectively. Interactions were run across 
the eight treatment options between insurance arrangements and geographical regions 
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(four census regions and urban/rural settings). The estimates of those interactions were 
analyzed in chapter three. 
All analyses were performed using person-level national weights constructed with 
the Household Component of the Medical Expenditure Panel Survey (MEPS) 98 , which 
provides estimates of the number of people with employer-sponsored private health 
insurance in the U.S. The person-level weights reflect the ratio of MEPS-based estimates 
in the different age/gender/region categories and the MarketScan number in the same 
category. In order to adjust our sample of interest so that its marginal totals match 
specified MEPS totals on the specified set of variables, we used the SAS Raking Macro, 
developed by Izrael and Colleagues. 75 Hence, our results are representative of the 
privately insured population in the U.S. The accuracy of the estimates between 
medication groups and the predictors of interest described in table 5 were tested using the 
methods by Bonferroni and the Bootstrap inference (10,000 bootstrap samples), applying 
techniques described elsewhere. 76 All analyses were run using SAS software, release 9.3 
(SAS Institute, Cary, NC, 1996) 
RESULTS 
Table 6 reports the utilization rates and the unweighted predictors for each type of 
medication treatment. A total of 753,007 individual subjects met our inclusion and 
exclusion criteria. Among them, 14% received medication monotherapy. Of those, 23% 
received SSRis, 17% received SNRis, 15% received TCAs, 3% received NASSAs, 32% 
received NDRis, 2% received SGAs and 8% received "other" antidepressants. A total of 
647,758 individuals (86%) did not receive medication treatment. Analysis by generation 
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class reported that 15% received first generation "older" antidepressants (TCA), 40% 
received second generation (NDRI and miscellaneous), 43% received third generation 
(SSRI, SNRI, and NASSA) and 2% received off label treatment (SGA). Of all adults with 
depression, 8% received psychotherapy alone and 1.1% received combination treatment 
(any medication plus psychotherapy). 
Table 7 reports the unadjusted, · weighted bivariate association between 13 
predictors and treatment utilization. Overall, MHS reported an increased likelihood of 
choosing TCAs (OR:1.20; CI:1.12-1.28), NASSAs (OR:2.00; CI:1.79-2.24), SGAs 
(OR:2.00; CI: 1.75-2.29), and miscellaneous (OR: 1.42; CI: 1.31-1.53), over SSRis, 
compared to PCPs .. Also, MHS are more likely to use combination therapy (OR:19.87; 
CI:19.2-21.68). 
For insurance type, capitated plans (HMOs or POS) had an increased likelihood 
of using combination treatment, compared to Fee-for service (OR: 1.54; CI: 1.29-1.84). 
With respect to monotherapy medication, capitated insurance options, are more likely to 
use SSRis over the other medication classes, compared to fee-for service plans (SNRI 
(OR:0.73; CI:0.62-0.86), TCA (OR:0.66; CI:0.56-0.78), NASSA (OR:0.43; CI:0.34-
0.54), SGA (OR:0.35; CI:0.26-0.47, and Miscellaneous (OR:0.68; CI:0.55-0.84)) except 
NDRis, for which the probability is the same. Also, SGAs are more likely to be used than 
SSRis in fee-for-service plans compared to the rest of managed care plans. The effect 
magnitude changes from OR:0.35 (capitated HMO and POS) to OR:0.61 (POS), 
In terms of regional differences, the Southern region of the country was less likely 
to use combination therapy, compared to the other three regions [Midwest (OR:1.38; 
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CI:1.29-1.48), Northeast (OR:1.27; CI:1.18-1.36), and West (OR:2.03; CI:1.90-2.17). 
Table 8 reports the independent predictors on the multivariable logistic 
regression, controlling for demographics, physical and mental comorbidities, disease 
severity, and regional differences. Concerning provider type, compared to the unadjusted 
results, the effect and direction of the associations across drug classes remained similar, 
except for NDRI (MHS are more likely to use the latter over SSRis, compared to PCPs 
(OR:1.13(1.05-1.22). For type of insurance, the associations described in the unadjusted 
analysis remained similar for combination therapy, NASSAs and TCAs. With respect to 
SNRis, the direction shifted from an overall, non-significant, negative effect to a positive 
one for Consumer-driven Health Plans (SNRis were more likely to be used over SSRis in 
CDHP settings, compared to fee-for-service [OR:1.39; CI:1.08-1.79]). For age 
differences, older adults were still more likely to use combination therapy than younger 
adults, however the difference became non-significant between middle age (27-44) and 
younger adults (18-26), compared to the unadjusted analysis. 
For gender, the unadjusted model showed a difference for the combination 
therapy and SNRI utilization between men and women, the differences disappeared in the 
fully adjusted models. The effects, direction, and significance of the remaining 
monotherapy medications remained similar to the unadjusted results. 
For region, the utilization of combination therapy, TCAs, SGAs and 
miscellaneous drugs remained stable, when compared to the unadjusted results. On the 
other side, SNRis and NASSAs differences reported in the unadjusted model went away 
in the adjusted version. On the other hand, utilization differences among NDRis appeared 
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(the West was more likely to use them over SSRis, compared to the South (OR:l.12; 
CI: 1.03-1.22). 
For urban/rural differences, the differences reported in the unadjusted model for 
combination therapy, SNRis, TCA and NASSA were gone in the adjusted version. The 
effects, direction, and significance of NDRis and SGAs remained comparable to the 
unadjusted version. 
In regards to incentives for offering mental health/substance abuse services, the 
unadjusted model showed a positive effect of having the incentive in place and receiving 
combination therapy or NASSA. Such associations were not present in the adjusted 
model. On the other hand, SGAs were less likely to be used over SSRis when the 
incentives were present (OR: 0.95; CI:0.79-1.14). With respect to psychotherapy, 
significant differences reported in the unadjusted models for SNRis, TCAs, NASSAs, 
NDRis, and miscellaneous disappeared in the adjusted models. On the other hand, it was 
less likely to use a SGA if psychotherapy was present (OR:0.91 ; CI:0.72-1.15). 
Concerning disease severity, combination therapy was less likely to be used in 
subjects with MDD, compared to dysthymia (OR:0.75; CI:0.67-0.84) (The unadjusted 
model reported the opposite effect). Regarding SNRis, TCA, and SGAs over SSRis, they 
were no longer more likely to be used in MDD compared to dysthymia, as the unadjusted 
model reported. For NASSAs, they were more likely to be used over SSRis for 
unspecified depression, compared to dysthymia. For NDRis, they were less likely to be 
used over SSRis for unspecified depression, compared to dysthymia. 
As to the major reason for the outpatient visit, the effects, direction, and level of 
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significance remained the same across the adjusted models. With respect to treatment 
persistence over a 6-month period, using combination therapy, NASSA, or SGA became 
non-significant predictors in the adjusted models. The positive effect of SNRis, TCAs 
remained similar as in the unadjusted models and miscellaneous antidepressants were 
negatively associated with achieving 6 months of treatment. 
In terms of copayment, the effect, direction and significance across all the models 
was similar to the results of their unadjusted counterparts, except for miscellaneous 
medication (one dollar increase did not change the likelihood of receiving miscellaneous 
medications over SSRis). 
Regarding comorbidities, the Elixhouser index was not a significant predictor for 
any of the therapy classes in this study. The p-values for the association between 
treatment choices and all the predictors remained stable using Bonferroni and 
Bootstrapping methods (detailed results shown in the appendix). 
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DISCUSSION 
The current study sheds light on insurance factors predicting treatment of 
depression in adults. First, our data demonstrates that pharmacologic monotherapy takes 
precedence in current practice for treatment of depression. Even though monotherapy 
medication was by far the most prevalent treatment option compared to psychotherapy, 
less than 20% of our sample of depressed adults received any of the treatment options 
explored. 
Among those that did receive treatment, the utilization across insurance 
arrangements varied widely. We found that combination therapy was more likely to be 
used by capitated plan types, compared to fee-for-service. Previous literature suggest that 
managed care may be more likely to comply with standard guidelines and formularies 
compared to less restrictive insurance arrangements. 18,2° ,99,100 With respect to 
monotherapy medication overall, MC was less likely to utilize TCA, NASSA and SGAs 
compared to fee-for-service. On the other hand, high deductible plans tend to utilize more 
often the NDRI class. These results suggest that more established medication therapy 
with more robust evidence supporting their effectiveness are being used in MC settings. 
Before the 1960s, healthcare insurance in the US was dominated by fee-for-
service arrangements. Since the implementation ofMC more than several decades ago, its 
ability to offer enrollees the benefits needed to tackle depression (regardless of severity) 
have been challenged. Benefits to treat depression have been historically neglected and 
not properly offered. 49 Even though the concerns were justifiable when MC was 
introduced, the amount and quality of services is different than years back and nowadays 
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is comparable to fee-for-service arrangements. Considering combination treatment as the 
most desirable option to treat any depression, several differences stand up between MC 
and fee-for-service: first, despite the perception of "restrictiveness" of many of the 
arrangements offered by MC, almost all Health Maintenance Organizations (HMO) 5 
provide a large amount of mental health services to their enrollees since the 1990s (in-
house or contracted). 99 Also, individual practice associations (IP A) are now standard 
practice to carve-out mental health/substance abuse services in MC. Such arrangements 
transfer in-house mental health services to contracts within networks run by independent 
providers. Published evidence has shown an increase in guideline-concordant treatments 
when carve-outs were present. 101 Our findings support that evidence. Second, 
approximately 50% of mental health problems (symptoms of anxiety or depression) are 
treated exclusively now by mental care specialists in MC settings (the percentage is 
similar within fee-for-service). These percentages will likely increase significantly in the 
future. 99 The remaining 50% receive mental health services in PC settings (true for both 
MC and fee-for-service scenarios). Yet, the depth and technical skill of generalists to 
provide accurate assessment and sound treatment to these individuals is more restrictive 
compared to their specialist's counterparts, and opportunities to properly detect 
depression are lost. In addition, health workers in HMO environments are explicitly 
governed by the need to please informed buyers who are spending at the margin their 
own money in terms of deductibles and copayment arrangements. This characteristic 
matches with the individual preference for receiving psychotherapy to treat depression. 102 
5 HMOs were the first type of managed care and their systematic introduction started in 1973 
after the enactment ofthe "Health Maintenance Organization Act" 
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On the other hand, fee-for-service arrangements respond to diverse influences that may 
not be tied to consumer preferences or cost-effectiveness assessment. 99 Correspondingly, 
MC offers more systematic opportunities to feature continuity of care, which 
accomplishes better health outcomes for mental disorders. 103,104 If an individual prefers 
continuity of care in fee-for-service arrangements, the intrinsic variability of providers 
and clinics under this setting might hinder this option. 105 Moreover, the financial 
pressure over MC to control cost of mental services forces the scrutiny of essential 
treatment tools based on population-based care management and financial experiments to 
reward mental health status improvements rather than strict adherence to policy 
exclusions and limits 99 . Such motivational incentives are not present in fee-for-service 
environments. 
The rates of monotherapy medication were also different between healthcare 
providers. While MRS prefer to utilize TCAs, NASSAs, NDRis and SGAs over SSRis, 
PCPs are more likely to treat with SNRis and SSRis. These differences in treatment 
choice may be partly explained by the fact that MHS are closer to the initial research 
literature, which tends to be published in specialty journals and conducted in specialty 
populations. MHS, therefore, may be more on the leading edge of new technological 
developments in depression treatment and more willing to try beforehand the most 
innovative treatments. Thus, despite the fact that the information about newer treatment 
choices (preferred by MHS) have more than a decade of existence after their initial 
marketing, PCPs may require even longer time frames to disseminate the utilization of 
new technologies and make them "standard care" in primary care. There also may exist 
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other barriers to the appropriate recognition and management of depression in primary 
care, such as PCP's interest and training, societal stigma, and health plan reimbursement. 
106 For example, it has been acknowledged that primary care providers often feel less 
confident to deal with severe cases of depression. 60•80 
Even though almost every clinical guideline recommends as desirable the 
combination of pharmacotherapy and some version of psychotherapy, less than five 
percent received this option in our nationally representative sample. Current barriers 
around psychotherapy, especially under primary care settings, may partly explain these 
low rates. Even though psychotherapy is considered time intensive, lengthy and mentally 
demanding (current guidelines recommend 12 to 20 1-hour sessions to be considered 
efficacious) the reduction of both duration and intensity of current psychotherapies 
without sacrificing effectiveness should be considered and explored. A systematic review 
done in 2011 suggest that about 7 sessions of brief psychotherapy are more efficacious 
(moderate clinical effect) than the control for the treatment of depression in primary care 
102
. If our main goal is to enhance the response to mental illness in primary care settings, 
such innovative strategies need to be discussed further including economic feasibility and 
technical availability. 
For regional variation, proposed guidelines and formularies may rmse 
controversies within provider groups about alternative therapies and additional 
information may be needed to settle the different opinions. Before that happens, different 
approaches may be considered "proper treatment" in different regions. For example, 
provider groups located in urban areas may be more likely to adapt to more innovative 
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and newer treatment options compared to providers practicing medicine in more rural, 
isolated areas. Such differences may be explained by information sources, resources 
availability, and adaptability to change. Our data suggest that combination therapy 
happens less often in the South compared to the other regions in the country. 
In terms of urban/rural differences, the former utilizes both NDRI (fewer side 
effects compared to other antidepressants) and SGAs (off-label for depression) more 
often than their rural counterparts. Our data and published literature suggest that rural 
settings may delay the introduction of newer and "higher tier" versions of medication 
therapy compared to urban settings. 14,107 This "conservative" effect may be protective for 
therapies with higher level of uncertainty as explained before, and providers practicing in 
rural areas may be less likely to use medication off-label. Future research will evaluate if 
the patterns of use of medications within different insurance arrangements are similar 
across regions and residential areas in the US. 
We should also acknowledge several limitations. First, our findings may not 
generalize to health care systems with different structure, fmancial incentives, or provider 
training. Second, even though we were interested in assessing psychotherapy, 
MarketScan only captures the formal version of this kind of therapy (psychotherapy). It is 
possible that providers offer and practice less formal and time intensive versions of 
therapy that are not captured in the data. Even though we tried to have a "clean period" of 
both diagnosis and pharmacologic treatment (6 month period) to rule out resistant 
depression, we recognize that a portion of our sample may not represent "first visit" 
patients. We ran additional analysis to assess the distribution of three different severity 
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categories (mild, moderate and severe depression) across the insurance plans (no 
significant differences), selection bias can't be fully controlled (for example previous 
literature has found that HMOs tend to have younger and less complicated subjects 
compared to fee-for-service, which may have an influence over our results). Although 
we used four different approaches to control for severity and complexity of our subjects, 
the effects of unmeasured confounders on treatment decisions are usually unknown. 
Future research could apply propensity scores or instrumental variables to decrease the 
confounding effect. This study could not control for detailed clinical information, which 
may improve the prediction capacity of our models (the c-statistic for our six medication 
monotherapy models varied from 0.64 to 0.69). 
Mental health recommendations and PCP's busy schedules seem to move in 
opposite directions. Even though some form of psychotherapy therapy (e.g. CBT, 
supportive therapy) plus the combination of evidence-based medication still offers the 
maximum benefit while minimizing risks for adults with mild to moderate depression, 
PCPs do not have the time 108 nor the proper training for such an approach. 
Innovative solutions are necessary to increase the frequency of optimal treatment 
utilization. 
Concerning short-term interventions, primary care settings may increase patient 
satisfaction and treatment effectiveness 109•110 by including some sort of psychotherapy 
that goes beyond what's currently offered besides medication (advice and reassurance) 
m_ Published literature found that patients stated a preference for psychotherapy to treat 
their mental conditions, compared to medication mono-therapies. 112•113 Also, compared 
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to other psychotherapy approaches [systemic behavior family therapy (SBFT), 
nondirective supportive treatment (NST)], CBT remains more effective with respect to 
clinical recovery, rate of symptomatic improvement, and parent-rated treatment 
expectancy and credibility. 114 Yet, PCPs current training level does not allow its 
utilization routinely. 
AACAP guidelines do recognize that other forms of psychotherapy such as NST 
may be feasible to implement in PCP settings because it can be mastered more easily, is 
effective for mild to moderate depression, and is a less specialized approach. NTS may 
have a better chance to be introduced in primary care settings in the short term, compared 
to CBT, which requires additional resources and training skills. 
Other providers different than physicians should be included to offer 
psychotherapy. For example, Unutzer and colleagues found that integrating psychologists 
into primary care settings significantly improves usual care for patients. 112 The creation 
of mental health treatment networks (internet-based) may be a feasible approach to 
enhance the response capabilities for mental disorders within primary care settings. 77 
Training programs should encourage the consolidation of pathways of 
consultation between primary care providers and mental health experts. That approach 
may be particularly effective for rural or marginalized clinics, who are largely isolated 
from longer and time consuming urban training options. 
Regarding long-term interventions, the paucity of evidence about the impact of 
psychotherapy training among physicians undermines any initiative to improve the 
situation. The implementation of psychotherapy in primary care settings is contingent 
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upon proper training for physicians, nurses, and other providers, and better coordination 
across the system to facilitate collaboration between PCPs and MHS. Also, systematic 
pathways to include CBT in primary care settings should be explored. For example, CBT 
has been taught in experiential instruction and residential programs, and both have been 
shown to be effective by increasing knowledge and making CBT techniques applicable 
after 1 year of training. 11 5 However, those time requirements may not be feasible for 
PCPs "in the field" and shorter training alternatives should be explored and evaluated. In 
addition, shorter training sessions of psychotherapy are needed to improve PCP's 
response capacity to treat mental disorders. Cully and colleagues in 2010 developed a 
formalized, multimodal, brief CBT training approach for mental health practitioners in 
primary care. The workshop lasted one day and a half and significantly improved both 
knowledge and self-reported abilities, and the effect was maintained at 3-month follow-
up 11 5• Finally, innovative approaches such as telepsychiatry (closed circuit TV) may be 
considered to complement live consultations in isolated areas 116. 
Final Comments 
Most adults with depression in privately insured settings are receiving limited or 
no treatment at all. From those receiving it, far too few are receiving guideline 
concordant treatment. The enhancement of primary care's ability to properly diagnose, 
manage, and treat depression in adults is warranted. The cost effectiveness linked to 
patient satisfaction when providers go beyond monotherapy medication and utilizes 
psychotherapy is explained by the decreased rates of resistant depression and relapse 
when the combination is preferred, which improves long-term treatment success 85,11 7 
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Factors outside medical norms and scientific knowledge (such as insurance arrangements 
and urban/rural settings) are significant drivers of treatment choice. Future research will 
demonstrate if such factors are similarly distributed across regions and residential areas in 
the US . 
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CHAPTER3 
Treatment utilization across insurance coverage and residential area on adults with 
depression: Geography matters 
ABSTRACT 
Objective. To examine the geographical variation of medication utilization rates across 
insurance arrangements and areas of residence among privately insured adults with 
depression. 
Methods. 
Data source. A privately insured population (Truven Analytics 2011) 
Design. Retrospective observational study of 2011 U.S. nationally representative data 
sample. 
Data subjects. Study sample included 90,198 adults with depression that received at least 
one medication option. 
Measurements. The likelihood of receiving seven different depression treatment options 
(any medication plus psychotherapy, SSRis, TCAs , SNRis, NDRI, NaSSA, SGA) by 
geographical region in the U.S. , in terms of three different insurance configurations (fee-
for-service, capitated, and PPO) 
Data Analysis: Seven mutually exclusive multivariable logistic regression models were 
applied. 
Results. A total of 90,198 subjects received any medication in 2011. From those, 35% 
received NDRI, 25% received SSRis; 19% received SNRis, 16% received TCAs, 8% 
received other antidepressants, 3% received NASSA and 2% received SGAs. 10% 
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received a medication plus psychotherapy. After controlling for individual characteristics, 
insurance type, region, residential area, mental health carve-out, medication copayment, 
treatment compliance and illness severity and complexity, Capitated arrangements in the 
south were between 2 to 5 times less likely to receive combination treatment compared to 
Capitated arrangements in the other three regions. Also, urban areas of residence were 
more likely to use combination therapy by 2 fold, compared to rural residents in capitated 
arrangements. 
Conclusions and Relevance. This study found large geographical variation that 
couldn't be explained on the basis of illness severity and complexity, out-of-pocket 
expenses, treatment compliance or subject's characteristics. Also, not all insurance 
arrangements behave similarly within regions. To differentiate this variability in terms of 
"acceptable vs "unacceptable" variation is important to continue tackling healthcare 
inefficiencies. Finally, the factors associated with population health in different 
residential areas are largely local, rooted in the environmental, social, economic, and 
behavioral determinants of health. While government and insurance compames are 
exactly right to develop financial incentives for health care providers, we should not 
forget that both health and health care are local and geography matters. 
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INTRODUCTION 
It is widely acknowledged that healthcare systems are poorly prepared to offer 
consistent and effective services for subjects with chronic and debilitating conditions 
104
,
118
. Within those conditions, mental health disorders are at the top of the list. 
Depressive disorders are the most prevalent conditions in the population and are 
considered serious, disabling illnesses. Approximately one in five persons is affected by a 
mood disorder at some point. 48 
The geographical factor has been described in the literature as a determinant of 
treatment of choice. 11 9 There are three main reasons why geography becomes important. 
First, many systems of health care are organized on a geographical basis. Hence, 
distribution of health care resources tailored to respond to local demands. Second, health 
care facilities such as hospitals and clinics are concentrated in specific locations, turning 
geography into a predictor of health utilization and outcomes. Third, there's substantial 
evidence that "area effects" are drivers of health inequality, after controlling for social 
and economic factors. 120 
Several area effects have been described in the literature. The physical 
environment partly explains health variation. For example, the local economic and labor 
conditions might create particular patterns of disease prevalence and incidence. Also, 
inadequacies in social support could deter health outcomes. For example, transportation 
inefficiencies, inappropriate education services or dangerous neighborhoods may create 
different environments for hospitals and clinics to operate. Other factors such culture and 
lifestyle may create area effects on health. 120 High income countries such as England are 
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aware of these concerns and have created "health action zones" to stimulate geographical 
policy response.121 For geographical variation and insurance arrangements, research has 
largely focused on traditional fee-for-service public health services (especially Medicare) 
and much less is known about utilization variation in the privately insured populations. 
For example, rural patients are likely to face greater travel barriers when undergoing 
depression treatment and some regions of the country are more likely to utilize 
psychotherapy as treatment of choice. 113 Also, regional differences concerning medicine 
practice style may explain medication variation across regions in the US . For example, 
the health and health care of rural Americans are more complex and more disadvantaged, 
compared to their urban counterparts in several important ways that affect their health. 
They are disproportionately poorer, fewer are of working age, and they have less 
education. 14 The rural U.S . has 20 percent of the national population, but less than 11 
percent of its physicians. 15 Rural versus urban residents are more often uninsured (18. 7 
versus 16.3 percent), more likely to report being in fair or poor health, have restricted 
activity, and lower levels of access to a regular primary care provider. 15 
More than three decades have passed since the Dartmouth Institute for Health 
Policy and Clinical Practice (Dartmouth) documented significant variation in Medicare 
utilization of services across geographical regions, producing a series of maps that have 
become known as the Dartmouth Atlas of Health Care. 122 Their findings showed that 
rates of utilization varied widely but did not appear to be consistently related to health 
outcomes or patient satisfaction among Medicare beneficiaries. This study will shed light 
about geographical variation of medication rates in a privately insured population and 
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assess if these differences stand in the private sector. 
Only a few studies have assessed the degree to which the type and benefit 
generosity of insurance arrangements contribute to measures of geographical variation in 
health care utilization. The effects of deductibles, copayment, gate-keepers, out-of-
network care and different degrees of specialty care access affect how much and what 
kind of health care is consumed. 123 For example, Baker and colleagues found larger 
variation in fee-for-service plans located in urban areas compared to Managed Care (MC) 
arrangements considering spending by payer type. 124 However, most of the literature 
involving geographical variation in health care revolves around price differences of 
technology, services, and products 125,126. 
The purpose of this study is to assess the geographical variation of antidepressant 
treatment utilization within insurance arrangements and residential areas in a nationally 
representative US sample of privately insured adults with depression. 
METHODS 
A cross sectional analysis was developed using a commercially available national 
data source (MarketScan Database) to identify a retrospective cohort of patients receiving 
an antidepressant to treat a new episode of mild or severe cases of depression in 2011. 
Using claims from the outpatient data source, patients between 18 to 64 years of age with 
new episodes of depression were identified according to the following criteria: (1) a 
claim indicating a primary or secondary (ICD-9-CM) diagnostic code of 296.2 or 296.3 
or 311 or dysthymia 300.4; (2) a 6 month "clean period" without a medication claim 
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(antidepressants and/or antipsychotics) before the depression claim date; (3) at least 6 
months without a depression diagnosis(es) or receipt of psychotherapy services (2 or 
more visits) before the depression claim date; and (4) at least twelve months of insurance 
coverage to ensure completeness. These inclusion criteria follows recommendations from 
the Health plan Employer Data Information System (HEDIS) for defining and measuring 
new episodes of depression. 96 This study was approved by the Boston Medical Center 
Institutional Review Board. 
Dependent variable: medication utilization 
Medication data was extracted from the outpatient pharmacy claims using the 
National Drug Code (NDC). At least one claim for antidepressant or SGA medication 
was defined as "any medication use" after the index diagnosis. Six monotherapy 
medication groups + one group defined as "any medication plus psychotherapy" 
(combination) were created. 
The medication classes to be identified and analyzed included: (1) SSRis; (2) 
TCAs; (3) SNRis; (4) NDRI; (5) NaSSA; (6) SGAs; and (7) Combination. The 
Combination category considered at least one medication claim and at least one session 
of psychotherapy. Table 1 reports the specific pharmaceuticals by class. 
Patients were grouped into one of these seven mutually exclusive treatment 
groups based on the first medication they received within 30 days of their episode 
diagnosis date. Patients who received an antidepressant within 30 days of their depression 
diagnosis but were initiated on more than one class that day, or were initiated on an 
antidepressant 30 days after their diagnosis, were excluded from the study cohort. 
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The main independent variable dealt with Geographical region. The performance 
of the health care system varies across different units of analysis, including physician, 
practice, plan type, and geographical unit. We defined "areas of different sizes" to 
determine how variation is affected by different levels of aggregation. For the present 
study, variation was examined at four geographical units of measurement: Northeast, 
Midwest, South and West. Table 9 shows the state distribution by region. 
Table 9. State distribution by Region 
Region States 
Northeast Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, 
New York, Pennsylvania, Rhode Island, and Vermont 
Midwest Indiana, Illinois, Iowa, Kansas, Michigan, Minnesota, Missouri, 
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin 
South Alabama, Arkansas, Delaware, District of Columbia, Florida, 
Georgia, Kentucky, Louisiana, Maryland, Mississippi, North 
Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, 
and West Virginia 
West Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, 
Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming 
We measured the interaction between our geographical variation and two factors: 
Insurance type and residential area. Regarding insurance type, three different categories 
were further analyzed: 1) Fee-for-service: the least restrictive plan considering out-of-
network service and specialist's availability. 2) Capitated Health Maintenance 
Organizations (HMO) or Point of Service (POS): The most restrictive option in terms of 
specialty availability and out of network services. 3) Patient Provider Organizations: 
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Individuals have financial incentives to use a particular list of providers. They can seek 
care outside of a network though. Except for fee-for-service, all insurance arrangements 
are considered "Managed Care". 
In terms of residential area, using the Metropolitan Statistical Area (MSA) we 
identified two categories: urban residence and rural residence 127. Our models controlled 
for the following variables: Physicians and non-physicians were classified into two 
mutually exclusive categories: a) Mental Health Specialists (MHS), represented by 
psychiatrists, child psychiatrists, psychologists and nurse psychologists and b) Primary 
Care Physicians (PCP), represented by internists, pediatricians, family physicians, 
general practitioners and nurses. Psychotherapy utilization was identified by CPT codes 
(90804-90809, 90853, 90847). Among demographic characteristics, we considered age, 
categorized into 3 groups (young adults [18-26 years], adults [27-44 years], and older 
adults [ 45- 64 years]); gender (male/female). In order to stratify patient severity and 
complexity, we included a) a severity index identifying three different depression 
diagnoses: major depressive disorder, dysthymia, and unspecified depression; b) the main 
reason of the visit (mental); c) The Elixhouser comorbidity Index 97; d) the existence of 
carve-out for mental illness and substance abuse. Having more than one mental disorder 
has been identified in the literature as a proxy of complexity among depressed 
individuals. 41 Guidelines suggest a minimum 6-month course of treatment to treat 
depression, hence, we calculated the number of months a subject kept receiving the 
treatment choice. We considered a subject adherent to treatment if they had at least 6 
months of pharmacy claims, allowing for no more than two months of discontinuation 
78 
within the 6-month time frame. We measured the likelihood of receiving psychotherapy 
while using the different types of antidepressant medication. 
Descriptive statistics are presented for the entire study population as well for 
strata defined within the four geographical regions: insurance type and residential area. 
The percentages of subjects receiving each type of treatment were calculated (Table 3). 
Prevalence estimates utilized either one of the following denominators: a) the total 
number of adults with depression as the denominator for those conditions including 
psychotherapy; and b) the total number of adults receiving at least one medication for 
those under pharmacologic treatment. Multiple logistic regression models calculated the 
estimates of the independent effects of insurance type and residential area within 
geographical regions on the likelihood of adults receiving one of the eight depression 
treatments. Results are presented as adjusted odds ratios with 95% confidence intervals. 
Confounding was checked by assessing the association between the dependent and main 
independent variable with each covariate. Collinearity was examined among all 
covariates with the variance inflation factor not exceeding 10. The expected performance 
and stability of the models were measured by the C-statistic and the Hosmer-Lemeshow 
test respectively. Interactions were run across the eight treatment options between 
insurance arrangements and geographical regions (four census regions and urban/rural 
settings). All analyses were performed using person-level national weights constructed 
with the Household Component of the Medical Expenditure Panel Survey (MEPS) 98, 
which provides estimates of the number of people with employer-sponsored private 
health insurance in the U.S . The person-level weights reflect the ratio of MEPS-based 
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estimates in the different age/gender/region categories and the MarketScan number in the 
same category. In order to adjust our sample of interest so that its marginal totals match 
specified MEPS totals on the specified set of variables, we used the SAS Raking Macro, 
developed by Izrael and Colleagues. 75 Hence, our results are representative of the 
privately insured population in the U.S. The accuracy of the estimates between 
medication groups and the predictors of interest described in tables 11-13 were tested 
using the methods by Bonferroni and the Bootstrap inference (10,000 bootstrap samples), 
applying techniques described elsewhere. 76 All analyses were run using SAS software, 
release 9.3 (SAS Institute, Cary, NC, 1996). 
80 
RESULTS 
Table 10 reports the utilization rates (unweighted numbers and weighted 
percentages) for each type of medication treatment by geographical variation and 
insurance arrangements. A total of 90,198 individual subjects received any monotherapy 
medication. Among them, 25% received SSRis, 19% received SNRis, 16% received 
TCAs, 3% received NASSAs, 35% received NDRis, and 2% received SGAs. 
Of all adults with depression, 11% received psychotherapy alone. From those, 10% 
received combination treatment (psychotherapy plus any medication). 
Weighted rates were higher for HMOs located in the west than for combination 
treatment (70%) compared to HMOs in the other regions (south and midwest 11% and 
northeast: 8%). For fee-for-service arrangements, the midwest region reported higher 
rates of SGA utilization (53%) compared to the other fee-for-service plans in the other 
regions (south:22; west:6%; northeast:19%). For PPOs, the south reported higher 
weighted rates of SSRI utilization (38) compared to PPOs in other regions (west:21 %; 
midwest:31 %; northeast: 11 %). 
Tables 11-13 report the weighted adjusted effects of geographical region by 
insurance arrangements, controlling for age, gender, depression severity, main diagnosis 
of treatment, residential area, carve-out mental health, provider type, out of pocket 
expenses, adherence to treatment, and the Elixhouser comorbidity index. 
For fee-for-service (Table 11), the likelihood of utilizing combination therapy is 
similar across regions and residential areas. However, regional differences were found 
with respect to different types of medications. The Midwest is less likely to use SNRis 
81 
compared to the south (OR:0.49; CI:0.28-0.87). The south is less likely to utilize TCAs 
compared to the northeast (OR:0.47; CI:0.23-0.96) and midwest (OR:0.53; CI:0.31-
0.91). NDRis were less likely to be used in the midwest (OR:0.51; CI:0.33-0.77) and 
northeast (OR:0.35; CI:0.20-0.61) compared to the west. In regards to urban vs. rural, the 
utilization of treatment options was similar across all regions. 
In relation to capitated HMOs or POS (Table 12), combination therapy was less 
likely to be used in the south compared to the northeast (OR:2.26; CI:l.64-3 .11), 
midwest (OR:2.53 ; CI:l.89-3.40) and the west (OR:5.21 ; CI:4.02-6.76). The west was 
more likely to use combination therapy than the midwest (OR:0.48; CI:0.40-0.57) and 
the northeast (OR:0.43 ; CI:0.35-0.52). The SNRI option was more often used (over 
SSRI) in the northeast compared to the south (OR: 1.33; CI: 1.04-1.71) and west (OR: 1.67; 
CI:l.35-2.05). For NDRis, their utilization was higher in the midwest compared to the 
south (OR:l.97; CI:l.72-2.25) and northeast (OR:2.14; CI:1.84-2.50). Second generation 
antipsychotics were more likely to be used in the northeast compared to the south 
(OR:l.89; CI:l.OS-3.40) and the west (OR:3.01; CI:l.72-5.27). Regarding residential 
area, urban settings more likely to be used combination therapy (OR:2.22; CI: 1.40-3 .53) 
and NDRI (OR:l.94; CI:l.57-2.38) and less likely to use SNRI (OR:0.76; CI:0.60-0.97) 
compared to rural settings. The p-values for the association between treatment choices 
and all the predictors remained stable using either Bonferroni or Bootstrapping testing 
(Appendix). 
With respect to PPOs (Table 13), combination therapy was more likely to be used 
in the northeast compared to the midwest (OR:l.16; CI:l.03-1.31), and west. The TCA 
82 
treatment option was less utilized (over SSRI) in the midwest compared to the south 
(OR:0.83; CI:0.76-0.91) and west (OR:0.83; CI:0.75-0.92). For NDRis, utilization was 
lower in the west compared to the midwest (OR:0.83; CI:0.75-0.92) and northeast 
(OR:0.62; CI:0.58-0.68). Second generation antipsychotics were less likely to be used in 
the south compared to the northeast (OR:l.67; CI:1.29-2.17) and the midwest (OR:1.26; 
CI: 1.02-1.55). In terms of residential area, urban settings more likely used TCA 
(OR:l.lO; CI:l.Ol-1.20), NDRI (OR:1.25; CI:l.l?-1.33), SGA (OR:1.33; CI:1.06-1.67), 
and NASSA (OR:1.20; CI:l.Ol-1.44). 
The p-values for the association between treatment choices and all the variable 
coefficients remained stable using Bonferroni and Bootstrapping testing after 1,000 
iterations. 
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DISCUSSION 
This study found large geographical variation that couldn't be explained on the 
basis of illness severity, adherence to treatment, or subject's characteristics throughout 
our results. Hence, this study was consistent with geographic differences reported by the 
Dartmouth Institute for Health Policy and Clinical Practice research. 128 First, 
geographical variations in technology use are substantial, pervasive and persistent, ruling 
out just random noise. Second, adjusting for individual's characteristics, disease severity 
and complexity, these variations are reduced, but not eliminated. Third, after controlling 
for all factors measurable within our data (age, sex, and health status, beneficiary 
demographic factors, compliance, insurance plan factors) , a large amount of variation 
was still explained by geographical and insurance factors across regions and residential 
areas. In contrast, the Dartmouth research did not find associations between geography 
and insurance when considering technology utilization in Medicaid data. This study 
found a large amount of utilization variability in the private sector, and not all insurance 
arrangements behave similarly within regions. 
A 2013 report from the Institute of Medicine suggested that variation should be 
able to distinguished between "acceptable" (different comorbidity profiles among 
subjects, different response to medication across age groups) and ''unacceptable" factors. 
Among the latter, unexplained variability across regions may be explained by market 
characteristics and discretionary provision of inefficient care. 129 This study found that 
overall, utilization of combination therapy was higher in capitated (HMO and POS) 
compared to fee-for-service and PPO arrangements. What explains such variability? 
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Previous literature identified Patient-based factors such as health status ethnicity 
' ' 
income, education, treatment preferences, and presence of insurance as predictors of 
regional variation in utilization patterns. Often, such variation is considered "acceptable" 
because these factors are beyond the control of both providers and individuals. For 
example, race is a variable mix of acceptable or unacceptable causes of variation. By 
contrast, provider-based factors (such as training, regional treatment norms, physician 
ownership, prevalence of fraud, and access to technology) may increase the chances of 
appropriate versus inappropriate or "unacceptable" treatment. 10 It is important to 
recognize these types of factors when reaching conclusions about why utilization varies 
from one part of the country to another. Unfortunately, it is often difficult to neatly 
classify the reasons behind variation and some factors can be controversial to control for 
geographical variation as described above. 
For geography, the amount of variability is different across studies. Some have 
found large differences of health status within regions (18% of geographical difference) 
130 or geographical variations of almost 70%. 131 Such variability is partly explained by 
the different geographical unit of analysis and the risk adjustment methodology. In 
addition to individual characteristics or insurance provisions, other factors such as local 
and regional markets for pharmaceuticals, supply of providers, hospital size, and level of 
competition among institutions may affect variation in health care utilization. For 
example, Wennberg and colleagues found that higher ratios of beds per capita (larger 
institutions) are associated with higher health care utilization in inpatient settings. 132 
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Another study found that higher percentage of PCPs predict lower spending per 
beneficiary within a region. 133 
Practice variation may also help to explain the geographical variation. Proposed 
guidelines and formularies may raise controversies within provider's practices about 
alternative therapies and additional information may be needed to settle the different 
opinions. Different concepts may be considered "proper treatment" in different regions. 
For example, provider groups located in urban areas may be more willing to adapt to 
more innovative and newer treatment options compared to the willingness of providers 
practicing medicine in more rural, isolated areas. Our data confirms this variability 
among NDRI (they are more likely to be used in urban areas, compared to rural ones). 
Such differences may be explained by information sources, resource availability, and 
adaptability to change. 
Our data also suggest that psychotherapy was used less often in the south 
compared to the other regions in the country. The rural and urban poverty rate gap for the 
south has historically been the largest, averaging 5.1 percentage points over the last two 
decades. 134 Also, rural poverty is deepest in certain parts of the south. Hence the lack of 
resources with respect to specialized providers and access to care may help to explain our 
findings. 
There are other factors that may also explain this geographical variation. Among 
those, insurance arrangements play an important role in US healthcare. 135 For example, 
different managed care policies and plans have varying influences in the marketplace by 
region and are often tailored by the industry marketing campaigns. In addition there are 
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differing regional influences of physician specialty groups. Also it's important to 
acknowledge the influence of direct-to-consumer advertising on patients and doctors, and 
different practice styles, values, and beliefs about medical practice. 9 Still, the reasons for 
this variation across treatment types warrant further research, Cox and colleagues 9 
introduced "the professional uncertainty theory", contending that variation in treatment 
options is positively associated with the level of uncertainty surrounding the diagnosis 
(which is high in mental health care). The source of information to choose the more 
adequate treatment options varies from site to site and from region to region, thereby 
introducing variation in the use of different options available. 
We should also acknowledge several limitations. First, our findings may not 
generalize to health care systems with different structure, financial incentives, or provider 
training. Second, even though we were interested in assessing combination therapy, 
MarketScan only captures the formal version of this kind of therapy (psychotherapy). It is 
possible that providers offer and practice less formal and time intensive versions of 
therapy that are not captured in the data. Even though we tried to have a "clean period" of 
both diagnosis and pharmacologic treatment ( 6 month period) to rule out resistant 
depression, we recognize that a portion of our sample may not represent "first visit" 
patients. Even though we ran additional analysis to assess the distribution of three 
different severity categories across the insurance plans (no significant differences), 
selection bias can't be fully controlled. For example previous literature has found that 
HMOs tend to have younger and less complicated subjects compared to fee-for-service. 
Such association may have an influence over our results. Also, our four geographical 
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regions may be too heterogeneous when considering provider behavior and insurance 
plan behavior, obscuring the true effect of medication utilization in less represented states 
regarding sample representation. Also, while multivariable regression analysis was used 
to adjust for confounders when assessing the associated effect of geography on 
medication utilization, unobservable confounders might have led to biased estimates. 
Several recommendations can be made with these results. Overall, the vast 
majority of studies address the regional variability in terms of price. 136-138 However 
utilization of different pharmaceutical and non-pharmaceutical treatment options across 
different geographical locations is sparse in the published literature. We would therefore 
argue that even though the price factor is an important predictor for privately insured 
populations, avoidable utilization may be easier to address than price. 10 Larger, more 
established HMOs such as Kaiser Permanente, Harvard Community Health Plan, the 
Fallon Clinic, Health Partners, have active research programs in the areas of public 
domain outcomes research and cost analyses, allowing the introduction of data uniformity 
and tighter guideline concordance. 99 Such focus on evaluating utilization patterns and 
outcomes should allow an effective identification of patients' follow-up for medication 
management and overall treatment response. This information can demonstrate to 
hospitals and insurance payers the consequences of under or overutilization of services in 
terms of costs of ootreated depression or the impact of premature termination of benefits 
or changes in copayments, shifting the explicit interest of avoiding uncontrollable costs to 
explicit effectiveness indicators. 99 Also, population-based care improves the 
coordination between provider categories, increasing communication between 
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professionals and collaboration when needed. 
MC reimbursement experiments provide prom1smg models for restructuring 
delivery systems based on rewards for guideline concordance based on follow-up health 
status and symptom remission. There are few, if any, treatment environments in which 
aggressive care management can be monitored as thoroughly as in MC. 99 Yet, MC need 
to be aware of potential pervasive consequences of population managed care, and avoid 
systematic characterization of high-cost psychiatric patients, denying them care. 
Moreover, MC need to increase the positive perception of patient satisfaction among the 
general public. 99 Making more and better data available and able to capture key system 
factors, is important to accurately assess the role of geography in healthcare. 
Final comments. 
Even though the current health reform underway in the United States focuses on 
changing the behavior of individual providers to increase access to health services, 
improve quality of care and decrease healthcare costs, the rationale for a geographical 
focus is strong, to the extent that the explained variation detected reflects system 
inefficiencies or different health care processes. The factors associated with population 
health in different residential areas are largely local, rooted in the environmental, social, 
economic, and behavioral determinants of health. Such factors also influence practice 
styles and approaches of outpatient care, including local supply, pricing behavior, 
financial incentives and the relative emphasis of providers on profit. There are lots of 
examples of such variation in the scientific and media publications. For example, 
93 
Wennberg and colleagues found small area variations m utilization, suggesting the 
considerable uncertainty about the effectiveness of different levels of aggregate, as well 
as specific kinds of health services. 11 Atul Gawande prepared an article for the New 
Yorker reporting how Medicare utilization was found to be nearly twice as high m 
McAllen compared to El Paso, two border towns in Texas, despite the existence of 
multiple hospitals in both McAllen and El Paso, nearly identical Medicare prices, and 
common Texas malpractice laws. 139 
While government and insurance companies are exactly right to develop financial 
incentives for health care providers, we should not forget that both health and health care 
are local and geography matters. 10 
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SECTION THREE 
Final Summary Remarks 
This thesis examined the utilization rates of several pharmacologic and non-
pharmacologic options of treatment for depression in a privately insured population in the 
US. Through my research, I address how private insurers can enhance the capacity of 
primary care providers to offer psychotherapy, identify insurance arrangements that may 
behave more closely to guideline concordance practices and highlight that geographical 
variation may help identify inappropriate care. 
Despite aforementioned limitations, this study made several important 
contributions to our understanding of mental health service utilization of medication and 
psychotherapy in children, adolescents and adults with depression. 
With regards to health policy implications, the present study shed light about 
mental health specialists and their approach to treat depression, which comes closer to 
current guidelines and formularies, compared to primary care providers. It is in the best 
interest of mental health services to offer primary care providers the necessary 
infrastructure, time and training to enhance depression therapy. There are several 
pathways available to accomplish this goal. First, health systems need to improve the 
early identification of people with depression by allowing consultation pathways between 
them and mental health specialists. This will reduce depression misdiagnosis and reduce 
the odds of resistant depression. Also, other providers such as psychologists and nurses 
should be trained to offer psychotherapy, helping address the shortage of physicians, 
especially troublesome in mental health services. Second, the private insurance design 
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makes a difference in terms of the treatment provided. Historically, managed care was 
considered not a good tool to tackle mental disorders. This study reports that restrictive 
insurance arrangements such as HMOs may increase the chances of following 
formularies recommendations by physicians more often compared to fee-for-service. 
Therefore, physicians under managed care contracts offer guideline concordant treatment 
more often when compared to fee-for-service. Also, literature has suggested that 
managed care may offer a better environment to treat long-term conditions such as 
mental disorders. Consequently, established HMOs such as Kaiser Permanente may offer 
guidance to increase the chances of enhancing pharmacotherapy by increasing the 
frequency of psychotherapy utilization. We need to meet two conditions first to allow 
this. First, help physicians recognize the value of psychotherapy in terms of patient 
satisfaction and therapy effectiveness. Second, health services want to offer shorter and 
more effective avenues to train PCP in this field. Previous research has shown that 
training periods as short as 8 weeks could be enough to expect positive results. 
As suggested by the adaptation of the IOM model, this study shows how 
utilization of services are associated with geographical variation and determinants of 
insurance type such as plan characteristics have a role in the decision-making of 
providers regarding antidepressant treatment. These findings expand our knowledge of 
within-region variability in mental health services and provide a springboard for future 
research in pharmacotherapy utilization and small area variation. 
Also, not all insurance arrangements behave similarly within regwns and to 
differentiate "acceptable vs. "unacceptable" variation IS important to start tackling 
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healthcare inefficiencies. In conclusion, the factors associated with population health in 
different residential areas are largely local, rooted in the environmental, social, economic, 
and behavioral determinants of health. While government and insurance companies are 
exactly right to develop financial incentives for health care providers, we should not 
forget that both health and health care are local and geography matters. 
In terms of future research, the findings of this study should be corroborated by a 
longitudinal design that can track utilization patterns over time. Also, to differentiate 
therapy between children and adolescents may strength this study by offering a more 
robust conclusion regarding optimal treatment. In addition, a qualitative study with the 
parents of children and adolescents with depression may help explain patient preferences 
regarding pharmacotherapy and psychotherapy, offering additional information about 
patient satisfaction and long-term outcomes of antidepressant therapy. Lastly, it is 
important to understand the mechanism of capitated arrangement insurance plans in the 
west to treat depression. A future study design combining qualitative and empiric work 
(mixed method approach) may help explain the differences to other regions in the U.S . 
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Governmental Tuberculosis Laboratories "National Institute of Thorax" Practical training: 
Smears, instrumentation registration and programming management of TB cases, and 
laboratory supplies, Bolivia. Certified, 2005. 
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LANGUAGE SKILLS 
Spanish: Native; English: Fluent, French: Reading Fluency, Portuguese: Reading Fluency 
PUBLICATIONS 
Peer Reviewed 
• Soria-Saucedo Rene. Harmful use of Alcohol (Alcohol Use Disorders and Alcoholic Liver 
Diseases). Priority Medicines for 
Europe and the World "A Public Health Approach to Innovation" 2013 . Available at: 
httQ://www. who.int/medicines/areas/Qriority medicines/BP6 14Alcohol.Qdf 
• Ledo C, Soria R. Sistema de salud de Bolivia. Salud Publica Mex 2011 ;53 supl 2: S 109-
S119. Available at: 
httQ:/Ibvs.insQ.mx/rsQ/ files/File/2011 /vol%2053%20sunlemento%202/7Bolivia.Qdf. 
• Soria-Saucedo Rene, Wirtz J . V, Avila-Burgos L. Analysis of prices, 
availability and affordability of medicines in public and private 
pharmacies in Mexico City. Febrero 2011. Available at: 
httn://www .haiweb.orgimedicineQrices/surveys/200912MX/sdocs/Medicines nnces avail 
ability and aseguibility in Mexico city.Qdf. 
• Soria-Saucedo Rene, Wirtz Veronika J, Kaplan Warren A. The volume share of generic 
medicines in the retail market between 1999 and 2009: a comparison between Brazil and 
Mexico. Third International Conference for Improving Use of Medicines (ICIUM). 14-18 
November, Antalya, Turkey, 2011. Available at: 
httQS :/ /www .conftool.comliciurn20 11 /index. QhQ ?nage=browseSessions&form session=8. 
Book Chapters 
Ministry of Health Mexico. Monitoring Ambulatory Performance. Sixty proposals to 
Strengthen Primary Health Care in the State Health Services. First Edition. 2011. 
Technical Reports 
• The World Justice Project: Rule of Law Index. Contributing Expert, Chapter Bolivia. 2012 . 
• National Institute of Public Health: Patents, prices and policies: Access to medicines for 
priority diseases in Mexico". Final Project Report prepared for the Ford Foundation. 2010. 
• Health Action International: Regulation assessment of pharmaceutical promotion and 
industry practices regarding publicity in AIS-LAC network (Argentina, Bolivia, Brazil, 
Colombia, Ecuador, Nicaragua and Peru) . AIS-LAC, 2008. 
• Consumers International: Promoting ethical and responsible consumption of medicines in 
Latin America (Argentina, Bolivia, Peru and Dominican Republic) ., 2008. 
• P AHO-CHU: Medicine prices in the Andean community and Nicaragua. Antiretroviral and 
oncology medicines in the public sector market, P AHO-CHU technical report. 
AIS/IFARMA, 2007. 
• Medicine Prices (Bolivia, Peru, Ecuador, Colombia, Venezuela and Nicaragua). Acci6n 
Internacional para la Salud, 
Oficina de Coordinaci6n America Latina y el Caribe, Lima, Peru, 2008 
Media 
• Health Diagnostic of a rural community in Morelos, Mexico (Alpuyeca), 2009. National 
Institute of Public Health, 2009. 
• Policy options to promote generic medicines in low and middle income countries. HAl-
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WHO project, 2011. 
• Counterfeit medicines: A public Health menace. AIS-Bolivia. Bulletin No 165, 2008 . 
• Zero Malnutrition: Development, Poverty, Hunger. AIS-Bolivia. Bulletin N° 164, 2008 . 
• Feeding Infants and Children Under 5 Years in Emergencies. AIS-Bolivia. Bulletin N° 163, 
2008. 
• Cooperation for development: efficient and effective aid? The Paris declaration. AIS-
Bolivia. Bulletin No 162, 2008. 
• Breastfeeding: Strategy for life, AIS-Bolivia, Bulletin N° 160, 2007 
• Breastfeeding: Saving millions oflives at the first hour, AIS-Bolivia, Bulletin N° 159, 
2007. 
• Global Call Against Poverty (GCAP) Bolivia. The Montevideo declaration, AIS-Bolivia 
Bulletin N° 158,2007. 
TEACHING EXPERIENCE 
Health Services Research and Methods 
Advanced Health Services Research and Methods 
Introduction to Pharmaceutical Assessment, Management, and Policy (P AMP) 
PROFESSIONAL SOCIETIES: 
Bolivian College of Medicine 
Health Action International Global (HAl) 
National Institute of Public Health Mexico/Public Health School of Mexico (INSP) 
Global Action to Call Against Poverty (GCAP) 
Latin America and Caribbean Network of Health Information Systems (RELACSIS) 
Consumers International (CI) 
Boston University School of Public Health (BUS PH) 
Center for the Assessment of Pharmaceutical Practices (CAPP) 
Academy Health Student Chapter (BU) 
